
<!DOCTYPE html>
<html lang="en" >
    <head >

        <meta charset="UTF-8" />
        <meta http-equiv="X-UA-Compatible" content="IE=edge" />
        <meta name="HandheldFriendly" content="True" />
        <meta name="MobileOptimized" content="320" />
        <meta name="viewport" content="width=device-width, initial-scale=1.0" />

        
        

        
        
  <link rel="stylesheet" href="/static/assets/style-a68b4900.css" />
<script type="module" crossorigin="" src="/static/assets/base_style-0a3f24ce.js"></script>

  <link rel="stylesheet" href="/static/assets/style-ef962842.css" />
<link rel="stylesheet" href="/static/assets/style-3ade8b5c.css" />
<script type="module" crossorigin="" src="/static/assets/article_style-d757a0dd.js"></script>

  
  
    <style>
  
  
  @media screen and (min-width: 64em) {
    div.pmc-wm {
      background: repeat-y;
      background-image: url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='20' height='350' xmlns:xlink='http://www.w3.org/1999/xlink'%3E%3Cdefs%3E%3Cfilter x='-.02' y='0' width='1.05' height='1' id='c'%3E%3CfeFlood flood-color='%23FFF'/%3E%3CfeComposite in='SourceGraphic'/%3E%3C/filter%3E%3Ctext id='b' font-family='Helvetica' font-size='11pt' style='opacity:1;fill:%23005ea2;stroke:none;text-anchor:middle' x='175' y='14'%3E%3C/text%3E%3Cpath id='a' style='fill:%23005ea2' d='M0 8h350v3H0z'/%3E%3C/defs%3E%3Cuse xlink:href='%23a' transform='rotate(90 10 10)'/%3E%3Cuse xlink:href='%23b' transform='rotate(90 10 10)' filter='url(%23c)'/%3E%3C/svg%3E");
      padding-left: 3rem;
    }
  }
</style>

  



        
            <link rel="apple-touch-icon"
                  sizes="180x180"
                  href="/static/img/favicons/apple-touch-icon.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="48x48"
                  href="/static/img/favicons/favicon-48x48.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="32x32"
                  href="/static/img/favicons/favicon-32x32.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="16x16"
                  href="/static/img/favicons/favicon-16x16.png" />
            <link rel="manifest" href="/static/img/favicons/site.webmanifest" />
            <link rel="mask-icon"
                  href="/static/img/favicons/safari-pinned-tab.svg"
                  color="#0071bc" />
            <meta name="msapplication-config"
                  content="/static/img/favicons/browserconfig.xml" />
            <meta name="theme-color" content="#ffffff" />
        

        <title>
            Ultrasound-Targeted Nanobubbles Codelivering NKP-1339 and miR-142-5p for Synergistic Mitochondrial Immunogenic Cell Death and PD-L1 Inhibition in Cancer Therapy - PMC
        </title>

        
        
  
  <!-- Logging params: Pinger defaults -->
<meta name="ncbi_app" content="cloudpmc-viewer" />
<meta name="ncbi_db" content="pmc" />
<meta name="ncbi_phid" content="4DDE466189B6F9731B466100502FD47F.m_1" />
<meta name="ncbi_pinger_stat_url" content="https://pmc.ncbi.nlm.nih.gov/stat" />
<!-- Logging params: Pinger custom -->
<meta name="ncbi_pdid" content="article" />
  
    <link rel="preconnect" href="https://www.google-analytics.com" />

    
        <link rel="preconnect" href="https://cdn.ncbi.nlm.nih.gov" />
    

    <!-- Include USWDS Init Script -->
    <script src="/static/assets/uswds-init.js"></script>


    <meta name="ncbi_domain" content="biomres">
<meta name="ncbi_type" content="fulltext">
<meta name="ncbi_pcid" content="journal">
<meta name="ncbi_feature" content="associated_data">
<link rel="canonical" href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12334082/">
<meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE">
<meta name="citation_journal_title" content="Biomaterials Research">
<meta name="citation_title" content="Ultrasound-Targeted Nanobubbles Codelivering NKP-1339 and miR-142-5p for Synergistic Mitochondrial Immunogenic Cell Death and PD-L1 Inhibition in Cancer Therapy">
<meta name="citation_author" content="Yafei Zhang">
<meta name="citation_author_institution" content="The First Affiliated Hospital , and College of Clinical Medicine of Henan University of Science and Technology, Luoyang 471003, China.">
<meta name="citation_author" content="Chaoqi Liu">
<meta name="citation_author_institution" content="Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy, China Three Gorges University, Yichang, Hubei 443002, China.">
<meta name="citation_author_institution" content="Medical College of China Three Gorges University, Yichang, Hubei 443002, China.">
<meta name="citation_author" content="Shuai Jin">
<meta name="citation_author_institution" content="The First Clinical Medical College of Three Gorges University, Center People’s Hospital of Yichang, Yichang, Hubei 443008, China.">
<meta name="citation_author" content="Liangyun Xie">
<meta name="citation_author_institution" content="The First Affiliated Hospital , and College of Clinical Medicine of Henan University of Science and Technology, Luoyang 471003, China.">
<meta name="citation_author" content="Qianwen Xiao">
<meta name="citation_author_institution" content="The First Affiliated Hospital , and College of Clinical Medicine of Henan University of Science and Technology, Luoyang 471003, China.">
<meta name="citation_author" content="Jun Yao">
<meta name="citation_author_institution" content="The First Affiliated Hospital , and College of Clinical Medicine of Henan University of Science and Technology, Luoyang 471003, China.">
<meta name="citation_publication_date" content="2025 Aug 8">
<meta name="citation_volume" content="29">
<meta name="citation_firstpage" content="0232">
<meta name="citation_doi" content="10.34133/bmr.0232">
<meta name="citation_pmid" content="40785846">
<meta name="citation_abstract_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12334082/">
<meta name="citation_fulltext_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12334082/">
<meta name="citation_pdf_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12334082/pdf/bmr.0232.pdf">
<meta name="description" content="The combination of chemical immunotherapy and gene therapy holds great promise for malignant tumor treatment. Here, we developed an ultrasound-targeted liposome nanobubbles system (NKP-1339/miR-142-NBs) for precise codelivery of drugs and genes to ...">
<meta name="og:title" content="Ultrasound-Targeted Nanobubbles Codelivering NKP-1339 and miR-142-5p for Synergistic Mitochondrial Immunogenic Cell Death and PD-L1 Inhibition in Cancer Therapy">
<meta name="og:type" content="article">
<meta name="og:site_name" content="PubMed Central (PMC)">
<meta name="og:description" content="The combination of chemical immunotherapy and gene therapy holds great promise for malignant tumor treatment. Here, we developed an ultrasound-targeted liposome nanobubbles system (NKP-1339/miR-142-NBs) for precise codelivery of drugs and genes to ...">
<meta name="og:url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12334082/">
<meta name="og:image" content="https://cdn.ncbi.nlm.nih.gov/pmc/cms/images/pmc-card-share.jpg?_=0">
<meta name="twitter:card" content="summary_large_image">
<meta name="twitter:site" content="@ncbi">
    
    

    </head>
    <body >
        
    <a class="usa-skipnav " href="#main-content">
      Skip to main content
    </a>


        
            

<section class="usa-banner " aria-label="Official website of the United States government" >
    <div class="usa-accordion">
        <header class="usa-banner__header">
            <div class="usa-banner__inner">
                <div class="grid-col-auto">
                    <img aria-hidden="true"
                         class="usa-banner__header-flag"
                         src="/static/img/us_flag.svg"
                         alt="" />
                </div>

                <div class="grid-col-fill tablet:grid-col-auto" aria-hidden="true">
                    <p class="usa-banner__header-text">
                        An official website of the United States government
                    </p>
                    <span class="usa-banner__header-action">Here's how you know</span>
                </div>

                



















    
        <button
            type="button"
        
    
    class="usa-accordion__button usa-banner__button
           

           
               
               
               
               
            

           
           
           
           "
    aria-expanded="false"
    aria-controls="gov-banner-default"
    
    data-testid="storybook-django-banner"
    
    >
    
        

        
                    <span class="usa-banner__button-text">Here's how you know</span>
                

        
    
        
            </button>
        


            </div>
        </header>

        <div class="usa-banner__content usa-accordion__content"
             id="gov-banner-default"
             hidden>
            <div class="grid-row grid-gap-lg">
                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-dot-gov.svg"
                         alt=""
                         aria-hidden="true" />
                    <div class="usa-media-block__body">
                        <p>
                            <strong>Official websites use .gov</strong>
                            <br />
                            A
                            <strong>.gov</strong> website belongs to an official
                            government organization in the United States.
                        </p>
                    </div>
                </div>

                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-https.svg"
                         alt=""
                         aria-hidden="true" />

                    <div class="usa-media-block__body">
                        <p>
                            <strong>Secure .gov websites use HTTPS</strong>
                            <br />
                            A <strong>lock</strong> (
                            <span class="icon-lock">
                                <svg xmlns="http://www.w3.org/2000/svg"
                                     width="52"
                                     height="64"
                                     viewBox="0 0 52 64"
                                     class="usa-banner__lock-image"
                                     role="graphics-symbol"
                                     aria-labelledby="banner-lock-description"
                                     focusable="false">
                                    <title id="banner-lock-title">Lock</title>
                                    <desc id="banner-lock-description">
                                    Locked padlock icon
                                    </desc>
                                    <path fill="#000000"
                                          fill-rule="evenodd"
                                          d="M26 0c10.493 0 19 8.507 19 19v9h3a4 4 0 0 1 4 4v28a4 4 0 0 1-4 4H4a4 4 0 0 1-4-4V32a4 4 0 0 1 4-4h3v-9C7 8.507 15.507 0 26 0zm0 8c-5.979 0-10.843 4.77-10.996 10.712L15 19v9h22v-9c0-6.075-4.925-11-11-11z" />
                                </svg>
</span>) or <strong>https://</strong> means you've safely
                                connected to the .gov website. Share sensitive
                                information only on official, secure websites.
                            </p>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </section>

        

        
    
    
    

<div class="usa-overlay">
</div>



<header class="usa-header usa-header--extended usa-header--wide" data-testid="header" data-header >
    <div class="ncbi-header">
        <div class="ncbi-header__container">
            
                <a class="ncbi-header__logo-container" href="https://www.ncbi.nlm.nih.gov/">
                    <img alt="
                                  NCBI home page
                              "
                         class="ncbi-header__logo-image"
                         src="/static/img/ncbi-logos/nih-nlm-ncbi--white.svg" />
                </a>
            

            <!-- Mobile menu hamburger button -->
            



















    
        <button
            type="button"
        
    
    class="usa-menu-btn ncbi-header__hamburger-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Show menu"
    data-testid="navMenuButton"
    
    >
    
        

        
                <svg aria-hidden="true"
                     class="ncbi-hamburger-icon"
                     fill="none"
                     focusable="false"
                     height="21"
                     viewBox="0 0 31 21"
                     width="31"
                     xmlns="http://www.w3.org/2000/svg">
                    <path clip-rule="evenodd"
                          d="M0.125 20.75H30.875V17.3333H0.125V20.75ZM0.125 12.2083H30.875V8.79167H0.125V12.2083ZM0.125 0.25V3.66667H30.875V0.25H0.125Z"
                          fill="#F1F1F1"
                          fill-rule="evenodd" />
                </svg>
            

        
    
        
            </button>
        



            
                <!-- Desktop buttons-->
                <div class="ncbi-header__desktop-buttons">
                    
                        <!-- Desktop search button -->
                        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button
           "
    aria-expanded="false"
    aria-controls="search-field-desktop-navigation"
    aria-label="Show search overlay"
    data-testid="toggleSearchPanelButton"
    data-toggle-search-panel-button
    >
    
        

        
                            


    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true"    >
        
        <use xlink:href="/static/img/sprite.svg#search" />
    </svg>


                            Search
                        

        
    
        
            </button>
        


                    

                    <!-- Desktop login dropdown -->
                    
                        <div class="ncbi-header__login-dropdown">
                            



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button ncbi-header__login-dropdown-button
           "
    aria-expanded="false"
    aria-controls="login-dropdown-menu"
    aria-label="Show login menu"
    data-testid="toggleLoginMenuDropdown"
    data-desktop-login-button
    >
    
        

        
                                


    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true"    >
        
        <use xlink:href="/static/img/sprite.svg#person" />
    </svg>



                                <span data-login-dropdown-text>Log in</span>

                                <!-- Dropdown icon pointing up -->
                                


    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-less ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true"    data-login-dropdown-up-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_less" />
    </svg>



                                <!-- Dropdown icon pointing down -->
                                


    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-more ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true"    data-login-dropdown-down-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_more" />
    </svg>


                            

        
    
        
            </button>
        



                            <!-- Login dropdown menu -->
                            <ul class="usa-nav__submenu ncbi-header__login-dropdown-menu"
                                id="login-dropdown-menu"
                                data-desktop-login-menu-dropdown
                                hidden>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        








<a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
    

    Dashboard

    
</a>

                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        








<a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
    

    Publications

    
</a>

                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        








<a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
    

    Account settings

    
</a>

                                    </li>
                                
                                <li class="usa-nav__submenu-item">
                                    



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--outline ncbi-header__login-dropdown-logout-button
           "
    
    
    
    data-testid="desktopLogoutButton"
    data-desktop-logout-button
    >
    
        

        Log out

        
    
        
            </button>
        


                                </li>
                            </ul>
                        </div>
                    
                </div>
            
        </div>
    </div>

    <!-- Search panel -->
    
        <div class="ncbi-search-panel ncbi--show-only-at-desktop"
             data-testid="searchPanel"
             data-header-search-panel
             hidden>
            <div class="ncbi-search-panel__container">
                <form action="https://www.ncbi.nlm.nih.gov/search/all/"
                      aria-describedby="search-field-desktop-navigation-help-text"
                      autocomplete="off"
                      class="usa-search usa-search--big ncbi-search-panel__form"
                      data-testid="form"
                      method="GET"
                      role="search">
                    <label class="usa-sr-only"
                           data-testid="label"
                           for="search-field-desktop-navigation">
                        Search…
                    </label>
                    <input class="usa-input"
                           data-testid="textInput"
                           id="search-field-desktop-navigation"
                           name="term"
                           
                               placeholder="Search NCBI"
                           
                           type="search"
                           value="" />
                    



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    data-testid="button"
    
    >
    
        

        
                        <span class="usa-search__submit-text">
                            Search NCBI
                        </span>
                    

        
    
        
            </button>
        


                </form>

                
            </div>
        </div>
    

    <nav aria-label="Primary navigation" class="usa-nav">
        <p class="usa-sr-only" id="primary-navigation-sr-only-title">
            Primary site navigation
        </p>

        <!-- Mobile menu close button -->
        



















    
        <button
            type="button"
        
    
    class="usa-nav__close ncbi-nav__close-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Close navigation menu"
    data-testid="navCloseButton"
    
    >
    
        

        
            <img src="/static/img/usa-icons/close.svg" alt="Close" />
        

        
    
        
            </button>
        



        
            <!-- Mobile search component -->
            <form class="usa-search usa-search--small ncbi--hide-at-desktop margin-top-6"
                  role="search">
                <label class="usa-sr-only" for="search-field">
                    Search
                </label>

                <input class="usa-input"
                       id="search-field-mobile-navigation"
                       type="search"
                       
                           placeholder="Search NCBI"
                       
                       name="search" />

                



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                    <!-- This SVG should be kept inline and not replaced with a link to the icon as otherwise it will render in the wrong color -->
                    <img src="data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIGhlaWdodD0iMjQiIHZpZXdCb3g9IjAgMCAyNCAyNCIgd2lkdGg9IjI0Ij48cGF0aCBkPSJNMCAwaDI0djI0SDB6IiBmaWxsPSJub25lIi8+PHBhdGggZmlsbD0iI2ZmZiIgZD0iTTE1LjUgMTRoLS43OWwtLjI4LS4yN0E2LjQ3MSA2LjQ3MSAwIDAgMCAxNiA5LjUgNi41IDYuNSAwIDEgMCA5LjUgMTZjMS42MSAwIDMuMDktLjU5IDQuMjMtMS41N2wuMjcuMjh2Ljc5bDUgNC45OUwyMC40OSAxOWwtNC45OS01em0tNiAwQzcuMDEgMTQgNSAxMS45OSA1IDkuNVM3LjAxIDUgOS41IDUgMTQgNy4wMSAxNCA5LjUgMTEuOTkgMTQgOS41IDE0eiIvPjwvc3ZnPg=="
                         class="usa-search__submit-icon"
                         alt="Search" />
                

        
    
        
            </button>
        


            </form>

            
        

        <!-- Primary navigation menu items -->
        <!-- This usa-nav__inner wrapper is required to correctly style the navigation items on Desktop -->
        

        
            <div class="ncbi-nav__mobile-login-menu ncbi--hide-at-desktop"
                 data-mobile-login-menu
                 hidden>
                <p class="ncbi-nav__mobile-login-menu-status">
                    Logged in as:
                    <strong class="ncbi-nav__mobile-login-menu-email"
                            data-mobile-login-email-text></strong>
                </p>
                <ul class="usa-nav__primary usa-accordion">
                    
                        <li class="usa-nav__primary-item">
                            








<a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
    

    Dashboard

    
</a>

                        </li>
                    
                        <li class="usa-nav__primary-item">
                            








<a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
    

    Publications

    
</a>

                        </li>
                    
                        <li class="usa-nav__primary-item">
                            








<a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
    

    Account settings

    
</a>

                        </li>
                    
                </ul>
            </div>
        

        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           ncbi-nav__mobile-login-button ncbi--hide-at-desktop
           "
    
    
    
    data-testid="mobileLoginButton"
    data-mobile-login-button
    >
    
        

        Log in

        
    
        
            </button>
        


    </nav>
</header>

    
    
        

<section class="pmc-header pmc-header--basic" aria-label="PMC Header with search box">
    <div class="pmc-nav-container">
        <div class="pmc-header__bar">
           <div class="pmc-header__logo">
               <a href="/" title="Home" aria-label="PMC Home"></a>
           </div>
            <button
                    type="button"
                    class="usa-button usa-button--unstyled pmc-header__search__button"
                    aria-label="Open search"
                    data-ga-category="search"
                    data-ga-action="PMC"
                    data-ga-label="pmc_search_panel_mobile"
            >
                <svg class="usa-icon width-4 height-4 pmc-icon__open" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#search"></use>
                </svg>
                <svg class="usa-icon width-4 height-4 pmc-icon__close" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
            </button>
        </div>
        <div class="pmc-header__search">
            


<form class="usa-search usa-search--extra usa-search--article-right-column  pmc-header__search__form" id="pmc-search-form" autocomplete="off" role="search">
<label class="usa-sr-only" for="pmc-search">Search PMC Full-Text Archive</label>
<span class="autoComplete_wrapper flex-1">
<input class="usa-input width-full maxw-none" required="required" placeholder="Search PMC Full-Text Archive" id="pmc-search"  type="search" name="term" data-autocomplete-url="https://pmc.ncbi.nlm.nih.gov/autocomp/search/autocomp/"/>
</span>
<button
class="usa-button"
type="submit"
formaction="https://www.ncbi.nlm.nih.gov/pmc/"
data-ga-category="search"
data-ga-action="PMC"
data-ga-label="PMC_search_button"
>
<span class="usa-search__submit-text">Search in PMC</span>
<img
src="/static/img/usa-icons-bg/search--white.svg"
class="usa-search__submit-icon"
alt="Search"
/>
</button>
</form>
            <div class="display-flex flex-column tablet:flex-row tablet:flex-justify flex-justify-center flex-align-center width-full desktop:maxw-44">
                <ul class="pmc-header__search__menu">
                    <li>
                        <a class="usa-link" href="https://www.ncbi.nlm.nih.gov/pmc/advanced/" data-ga-action="featured_link" data-ga-label="advanced_search">
                            Advanced Search
                        </a>
                    </li>
                    <li>
                        
                            <a class="usa-link" href="/journals/" data-ga-action="featured_link" data-ga-label="journal list">
                                Journal List
                            </a>
                        
                    </li>
                    <li>
                        
                            <a class="usa-link" href="/about/userguide/" data-ga-action="featured_link"
                            data-ga-label="user guide">
                                User Guide
                            </a>
                        
                    </li>
                </ul>
                
                    <button form="pmc-search-form" formaction="https://pmc.ncbi.nlm.nih.gov/search/" type="submit" class="usa-button usa-button--unstyled hover:text-no-underline text-no-underline width-auto margin-top-1 tablet:margin-top-0">
     <span class="bg-green-label padding-05 text-white">New</span><span class="text-underline text-primary">Try this search in PMC Beta Search</span>
</button>
                
            </div>
        </div>
    </div>
</section>

    


        
        

       
  <div class="usa-section padding-top-0 desktop:padding-top-6 pmc-article-section" data-article-db="pmc" data-article-id="12334082">

    

   



<div class="grid-container pmc-actions-bar" aria-label="Actions bar" role="complementary">
    <div class="grid-row">
        <div class="grid-col-fill display-flex">
             <div class="display-flex">
                <ul class="usa-list usa-list--unstyled usa-list--horizontal">
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <button
                                type="button"
                                class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                                aria-label="Open resources"
                                data-extra-class="is-visible-resources"
                                data-ga-category="resources_accordion"
                                data-ga-action="click"
                                data-ga-label="mobile_icon"
                        >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#more_vert"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <a
                                href="https://doi.org/10.34133/bmr.0232"
                                class="usa-link display-flex usa-tooltip"
                                role="button"
                                target="_blank"
                                rel="noreferrer noopener"
                                title="View on publisher site"
                                data-position="bottom"
                                aria-label="View on publisher site"
                                data-ga-category="actions"
                                data-ga-action="click"
                                data-ga-label="publisher_link_mobile"
                        >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#launch"></use>
                                </svg>
                        </a>
                    </li>
                    
                    
                        <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                             <a
                                     href="pdf/bmr.0232.pdf"
                                     class="usa-link display-flex usa-tooltip"
                                     role="button"
                                     title="Download PDF"
                                     data-position="bottom"
                                     aria-label="Download PDF"
                                     data-ga-category="actions"
                                     data-ga-action="click"
                                     data-ga-label="pdf_download_mobile"
                             >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                                </svg>
                            </a>
                        </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button
                            class="usa-button usa-button--unstyled  usa-tooltip collections-dialog-trigger collections-button display-flex collections-button-empty"
                            title="Add to Collections"
                            data-position="bottom"
                            aria-label="Save article in MyNCBI collections."
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="collections_button_mobile"
                            data-collections-open-dialog-enabled="false"
                            data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12334082%2F%3Freport%3Dclassic%23open-collections-dialog"
                            data-in-collections="false"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button role="button" class="usa-button usa-button--unstyled usa-tooltip citation-dialog-trigger display-flex"
                            aria-label="Open dialog with citation text in different styles"
                            title="Cite"
                            data-position="bottom"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="cite_mobile"
                            data-all-citations-url="/resources/citations/12334082/"
                            data-citation-style="nlm"
                            data-download-format-link="/resources/citations/12334082/export/"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="pmc-permalink display-flex" >
                         <button
                                 type="button"
                                 title="Permalink"
                                 data-position="bottom"
                                 class="usa-button usa-button--unstyled display-flex usa-tooltip"
                                 aria-label="Show article permalink"
                                 aria-expanded="false"
                                 aria-haspopup="true"
                                 data-ga-category="actions"
                                 data-ga-action="open"
                                 data-ga-label="permalink_mobile"
                         >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#share"></use>
                            </svg>
                        </button>
                        

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12334082/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
                    </li>
                </ul>
            </div>
            <button
                    type="button"
                    class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                    aria-label="Open article navigation"
                    data-extra-class="is-visible-in-page"
                    data-ga-category="actions"
                    data-ga-action="open"
                    data-ga-label="article_nav_mobile"
            >
                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#list"></use>
                </svg>
            </button>
        </div>
    </div>
</div>
    <div class="grid-container desktop:padding-left-6">
      <div id="article-container" class="grid-row grid-gap">
        <div class="grid-col-12 desktop:grid-col-8 order-2 pmc-layout__content">
            <div class="grid-container padding-left-0 padding-right-0">
                <div class="grid-row desktop:margin-left-neg-6">
                    <div class="grid-col-12">
                        <div class="pmc-layout__disclaimer" role="complementary" aria-label="Disclaimer note">
    As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
    the contents by NLM or the National Institutes of Health.<br/>
    Learn more:
    <a class="usa-link" data-ga-category="Link click" data-ga-action="Disclaimer" data-ga-label="New disclaimer box" href="/about/disclaimer/">PMC Disclaimer</a>
    |
    <a class="usa-link" data-ga-category="Link click" data-ga-action="PMC Copyright Notice" data-ga-label="New disclaimer box" href="/about/copyright/">
        PMC Copyright Notice
    </a>
</div>
                    </div>
                </div>
                <div class="grid-row pmc-wm desktop:margin-left-neg-6">
                    <!-- Main content -->
                    <main
                      id="main-content"
                      class="usa-layout-docs__main usa-layout-docs grid-col-12 pmc-layout pmc-prose padding-0"
                    >

                      
                        <section class="pmc-journal-banner text-center line-height-none" aria-label="Journal banner"><img src="https://cdn.ncbi.nlm.nih.gov/pmc/banners/logo-biomres.png" alt="Biomaterials Research logo" usemap="#pmc-banner-imagemap" width="500" height="75"><map name="pmc-banner-imagemap"><area alt="Link to Biomaterials Research" title="Link to Biomaterials Research" shape="default" href="https://spj.science.org/journal/bmr" target="_blank" rel="noopener noreferrer"></map></section><article lang="en"><section aria-label="Article citation and metadata"><section class="pmc-layout__citation font-secondary font-xs"><div>
<div class="display-inline-block"><button type="button" class="cursor-pointer text-no-underline bg-transparent border-0 padding-0 text-left margin-0 text-normal text-primary" aria-controls="journal_context_menu">Biomater Res</button></div>. 2025 Aug 8;29:0232. doi: <a href="https://doi.org/10.34133/bmr.0232" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">10.34133/bmr.0232</a>
</div>
<nav id="journal_context_menu" hidden="hidden"><ul class="menu-list font-family-ui" role="menu">
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/pmc/?term=%22Biomater%20Res%22%5Bjour%5D" class="usa-link" role="menuitem">Search in PMC</a></li>
<li role="presentation"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Biomater%20Res%22%5Bjour%5D" lang="en" class="usa-link" role="menuitem">Search in PubMed</a></li>
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Biomater%20Res%22%5BTitle%20Abbreviation%5D" class="usa-link" role="menuitem">View in NLM Catalog</a></li>
<li role="presentation"><a href="?term=%22Biomater%20Res%22%5Bjour%5D" class="usa-link" role="menuitem" data-add-to-search="true">Add to search</a></li>
</ul></nav></section><section class="front-matter"><div class="ameta p font-secondary font-xs">
<hgroup><h1>Ultrasound-Targeted Nanobubbles Codelivering NKP-1339 and miR-142-5p for Synergistic Mitochondrial Immunogenic Cell Death and PD-L1 Inhibition in Cancer Therapy</h1></hgroup><div class="cg p">
<a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Zhang%20Y%22%5BAuthor%5D" class="usa-link" aria-describedby="id1"><span class="name western">Yafei Zhang</span></a><div hidden="hidden" id="id1">
<h3><span class="name western">Yafei Zhang</span></h3>
<div class="p">
<sup><sup>1</sup></sup>
The First Affiliated Hospital , and College of Clinical Medicine of Henan University of Science and Technology, Luoyang 471003, China.</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Zhang%20Y%22%5BAuthor%5D" class="usa-link"><span class="name western">Yafei Zhang</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Liu%20C%22%5BAuthor%5D" class="usa-link" aria-describedby="id2"><span class="name western">Chaoqi Liu</span></a><div hidden="hidden" id="id2">
<h3><span class="name western">Chaoqi Liu</span></h3>
<div class="p">
<sup><sup>2</sup></sup>Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy, 
China Three Gorges University, Yichang, Hubei 443002, China.</div>
<div class="p">
<sup><sup>3</sup></sup>
Medical College of China Three Gorges University, Yichang, Hubei 443002, China.</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Liu%20C%22%5BAuthor%5D" class="usa-link"><span class="name western">Chaoqi Liu</span></a>
</div>
</div>
<sup>2,</sup><sup>3</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Jin%20S%22%5BAuthor%5D" class="usa-link" aria-describedby="id3"><span class="name western">Shuai Jin</span></a><div hidden="hidden" id="id3">
<h3><span class="name western">Shuai Jin</span></h3>
<div class="p">
<sup><sup>4</sup></sup>The First Clinical Medical College of Three Gorges University, 
Center People’s Hospital of Yichang, Yichang, Hubei 443008, China.</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Jin%20S%22%5BAuthor%5D" class="usa-link"><span class="name western">Shuai Jin</span></a>
</div>
</div>
<sup>4</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Xie%20L%22%5BAuthor%5D" class="usa-link" aria-describedby="id4"><span class="name western">Liangyun Xie</span></a><div hidden="hidden" id="id4">
<h3><span class="name western">Liangyun Xie</span></h3>
<div class="p">
<sup><sup>1</sup></sup>
The First Affiliated Hospital , and College of Clinical Medicine of Henan University of Science and Technology, Luoyang 471003, China.</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Xie%20L%22%5BAuthor%5D" class="usa-link"><span class="name western">Liangyun Xie</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Xiao%20Q%22%5BAuthor%5D" class="usa-link" aria-describedby="id5"><span class="name western">Qianwen Xiao</span></a><div hidden="hidden" id="id5">
<h3><span class="name western">Qianwen Xiao</span></h3>
<div class="p">
<sup><sup>1</sup></sup>
The First Affiliated Hospital , and College of Clinical Medicine of Henan University of Science and Technology, Luoyang 471003, China.</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Xiao%20Q%22%5BAuthor%5D" class="usa-link"><span class="name western">Qianwen Xiao</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Yao%20J%22%5BAuthor%5D" class="usa-link" aria-describedby="id6"><span class="name western">Jun Yao</span></a><div hidden="hidden" id="id6">
<h3><span class="name western">Jun Yao</span></h3>
<div class="p">
<sup><sup>1</sup></sup>
The First Affiliated Hospital , and College of Clinical Medicine of Henan University of Science and Technology, Luoyang 471003, China.</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Yao%20J%22%5BAuthor%5D" class="usa-link"><span class="name western">Jun Yao</span></a>
</div>
</div>
<sup>1,</sup><sup>*</sup>
</div>
<ul class="d-buttons inline-list">
<li><button class="d-button" aria-controls="aip_a" aria-expanded="false">Author information</button></li>
<li><button class="d-button" aria-controls="anp_a" aria-expanded="false">Article notes</button></li>
<li><button class="d-button" aria-controls="clp_a" aria-expanded="false">Copyright and License information</button></li>
</ul>
<div class="d-panels font-secondary-light">
<div id="aip_a" class="d-panel p" style="display: none">
<div class="p" id="aff1">
<sup><sup>1</sup></sup>
The First Affiliated Hospital , and College of Clinical Medicine of Henan University of Science and Technology, Luoyang 471003, China.</div>
<div id="aff2">
<sup><sup>2</sup></sup>Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy, 
China Three Gorges University, Yichang, Hubei 443002, China.</div>
<div id="aff3">
<sup><sup>3</sup></sup>
Medical College of China Three Gorges University, Yichang, Hubei 443002, China.</div>
<div id="aff4">
<sup><sup>4</sup></sup>The First Clinical Medical College of Three Gorges University, 
Center People’s Hospital of Yichang, Yichang, Hubei 443008, China.</div>
<div class="author-notes p"><div class="fn" id="corr1">
<sup>*</sup><p class="display-inline">Address correspondence to: <span>yaojun74@163.com</span></p>
</div></div>
</div>
<div id="anp_a" class="d-panel p" style="display: none"><div class="notes p"><section id="historyarticle-meta1" class="history"><p>Received 2025 Apr 23; Revised 2025 Jun 20; Accepted 2025 Jul 5; Collection date 2025.</p></section></div></div>
<div id="clp_a" class="d-panel p" style="display: none">
<div>Copyright © 2025 Yafei Zhang et al.</div>
<p>Exclusive licensee Korean Society for Biomaterials, Republic of Korea. No claim to original U.S. Government Works. Distributed under a <a href="https://creativecommons.org/licenses/by/4.0/" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Creative Commons Attribution License (CC BY 4.0)</a>.</p>
<div class="p"><a href="/about/copyright/" class="usa-link">PMC Copyright notice</a></div>
</div>
</div>
<div>PMCID: PMC12334082  PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40785846/" class="usa-link">40785846</a>
</div>
</div></section></section><section aria-label="Article content"><section class="body main-article-body"><section class="abstract" id="abstract1"><h2>Abstract</h2>
<p>The combination of chemical immunotherapy and gene therapy holds great promise for malignant tumor treatment. Here, we developed an ultrasound-targeted liposome nanobubbles system (NKP-1339/miR-142-NBs) for precise codelivery of drugs and genes to treat esophageal squamous cell carcinoma (ESCC) with ultrasound-targeted microbubble destruction (UTMD). This study systematically investigated the system’s therapeutic mechanisms—including mitochondrial dysfunction induction, immunogenic cell death (ICD), and antitumor immune activation—alongside its pharmacokinetics and targeting efficiency. In an ESCC mouse model, NKP-1339/miR-142-NBs combined with ultrasound markedly suppressed tumor growth (79.72% ± 0.1% vs. NB control 18.79% ± 1.29%) through NKP-1339 triggering ICD and miR-142-5p down-regulating programmed death-ligand 1 (PD-L1) expression, synergistically potentiating immune responses. Furthermore, we found that triggering ICD, including the exposure of calreticulin on the cell membrane, was related to altering mitochondrial fission dynamics in the ESCC cells. The down-regulation of PD-L1 expression by miR-142-5p reactivated CD8<sup>+</sup> T cells by relieving programmed death-1 (PD-1)/PD-L1-mediated immunosuppression, enhancing immune memory and antitumor efficacy. Moreover, the UTMD technique enhanced the tumoral accumulation and penetration of nanobubbles, improving delivery specificity and minimizing off-target effects. This combined treatment strategy, including UTMD, provides a promising translational potential for ESCC therapy.</p></section><section id="sec1"><h2 class="pmc_sec_title">Introduction</h2>
<p>Esophageal squamous cell carcinoma is the sixth-leading cause of cancer-related deaths and was responsible for 540,000 deaths in 2020 [<a href="#B1" class="usa-link" aria-describedby="B1">1</a>]. Despite the effectiveness of traditional treatments including surgery, radiotherapy, and chemotherapy, which induce apoptosis or necrosis in cancer cells through cytotoxic agents [<a href="#B2" class="usa-link" aria-describedby="B2">2</a>], these approaches are insufficient to prevent cancer recurrence [<a href="#B3" class="usa-link" aria-describedby="B3">3</a>]. Therefore, the development of novel and effective treatment strategies for esophageal cancer has become a critical issue requiring urgent attention.</p>
<p>Recently, immunotherapy is an effective treatment approach that activates the immune system to eliminate tumor cells, thereby preventing tumor recurrence and metastasis. However, immunotherapy faces numerous challenges in clinical oncology, including low immunogenicity and immunosuppressive tumor microenvironment (TME) [<a href="#B4" class="usa-link" aria-describedby="B4">4</a>]. Key features of this environment include exhausted cytotoxic T lymphocytes (CTLs), myeloid-derived suppressor cells, tumor-associated macrophages, and regulatory T cells [<a href="#B5" class="usa-link" aria-describedby="B5">5</a>]. Induction of immunogenic cell death (ICD) has gained considerable attention in cancer therapy. ICD is a form of immune stimulation-regulated cell death, in which dying cells serve as anticancer immunogens to activate immune responses [<a href="#B6" class="usa-link" aria-describedby="B6">6</a>]. It is one of the strategies used in anticancer immunotherapy and is capable of reversing the immunosuppressive TME, thus enhancing sensitivity to immunotherapy. Tumor cells undergoing ICD express tumor-associated antigens and damage-associated molecular patterns (DAMPs), such as surface exposure of calreticulin (CRT) (“eat me” signal), release of high-mobility group box 1 (HMGB1) (“danger” signal), and secretion of adenosine triphosphate (ATP) (“find me” signal). These ICD-associated DAMPs are captured and processed by antigen-presenting cells, and their interaction with dendritic cells (DCs) promotes the maturation and activation of antigen-specific immune responses [<a href="#B7" class="usa-link" aria-describedby="B7">7</a>]. This results in the activation of CTL-mediated immune responses, leading to the elimination of tumor cells. Therefore, the development of a safe and effective ICD induction strategy has become a promising and feasible approach for tumor immunotherapy, including the treatment of esophageal cancer.</p>
<p>Traditionally, cytotoxic chemotherapy has been associated with immunosuppressive effects such as those induced by platinum-based compounds [<a href="#B8" class="usa-link" aria-describedby="B8">8</a>]. However, clinical studies have demonstrated that a combination of chemotherapy and immunotherapy often produces synergistic effects. Ruthenium-based compounds have emerged as a promising candidate for cancer research owing to their unique mechanisms of action. Among these, NKP-1339, a ruthenium-based complex, sodium trans-[tetrachloridobis (1H-indazole)ruthenate-(III)] (also known as IT-139, KP1339, or BOLD-100), is a novel ICD inducer that has shown significant preclinical activity in various tumor models and has been well tolerated in clinical trials. NKP-1339 induces endoplasmic reticulum (ER) stress and tumor cell death by down-regulating GRP78 (BiP) and disrupting ER homeostasis [<a href="#B9" class="usa-link" aria-describedby="B9">9</a>]. Although some chemotherapy drugs such as doxorubicin, mitoxantrone, and platinum-based compounds can also induce ICD [<a href="#B10" class="usa-link" aria-describedby="B10">10</a>], the clinical availability of ICD inducers remains limited. Therefore, exploring the immunogenic potential of clinically used anticancer drugs and novel compounds is of great therapeutic significance. However, the targeted nature and nonspecific distribution of monotherapy limit its clinical efficacy [<a href="#B11" class="usa-link" aria-describedby="B11">11</a>]. Developing precise delivery platforms to deliver ICD inducers and achieve synergistic effects can markedly improve the therapeutic efficacy of NKP-1339, thereby amplifying the ICD effects and providing a new strategy for cancer immunotherapy.</p>
<p>Immune checkpoint blockade therapy is widely used in clinical practice, and one of its key targets is programmed death-ligand 1 (PD-L1). PD-L1 is highly expressed in most esophageal cancers and correlates with tumor invasiveness, overall survival, and postoperative recurrence, making it an important therapeutic target and potential biomarker. MicroRNA (miRNA) is a noncoding RNA that plays a crucial role in regulating gene expression within the tumor immune microenvironment [<a href="#B12" class="usa-link" aria-describedby="B12">12</a>]. miR-142-5p, a tumor-suppressive miRNA, targets PD-L1 to modulate the immune microenvironment and enhances cisplatin-induced apoptosis in ovarian cancer cells [<a href="#B13" class="usa-link" aria-describedby="B13">13</a>]. Additionally, miR-142-5p exerts anticancer effects by targeting PIK3CA in non-small cell lung cancer [<a href="#B14" class="usa-link" aria-describedby="B14">14</a>], and inhibits esophageal cancer progression by regulating epithelial–mesenchymal transition and stemness [<a href="#B15" class="usa-link" aria-describedby="B15">15</a>]. However, as miRNAs are nucleic acid-based drugs with short half-lives in vivo, there is a pressing need for efficient drug delivery systems to enhance their therapeutic efficacy.</p>
<p>Lipid microbubbles (MBs), used as drug and gene delivery carriers, effectively transport therapeutic molecules to tumor tissues via ultrasound (US)-targeted MB destruction, considerably enhancing their therapeutic effects [<a href="#B16" class="usa-link" aria-describedby="B16">16</a>]. However, traditional MBs, which typically range in size from to 1 to 4 μm, exhibit limited penetration within tumor tissues. Here, to overcome this limitation, we designed lipid NBs with a size range of 100 to 500 nm, enabling enhanced permeability and retention (EPR) effects that allow passive accumulation within tumor tissues, thereby considerably improving drug delivery efficiency.</p>
<p>Therefore, we developed a combined strategy for immunogenic chemotherapy and gene therapy using US nanolipid NBs (NKP-1339/miR-142-5P-NBs). This novel drug delivery system offers high biocompatibility and controllability, markedly enhancing tumor tissue permeability and drug targeting via US-triggered cavitation, thereby facilitating efficient drug delivery and precise drug release (Fig. <a href="#F1" class="usa-link">1</a>). Compared with conventional drug delivery methods, this system markedly increases drug concentrations at the tumor site while reducing systemic toxicity [<a href="#B17" class="usa-link" aria-describedby="B17">17</a>]. In vivo studies have shown that this mitochondrial stress-based immunostimulatory strategy can modulate immune cell activity, activating both the innate and adaptive immune systems, thereby reversing the immunosuppressive TME and markedly improving antitumor efficacy in esophageal cancer subcutaneous models.</p>
<figure class="fig xbox font-sm" id="F1"><h3 class="obj_head">Fig. 1.</h3>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><img class="graphic" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3dd3/12334082/36bea4d01c49/bmr.0232.fig.001.jpg" loading="lazy" height="612" width="660" alt="Fig. 1."></p>
<div class="p text-right font-secondary"><a href="figure/F1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Schematic representation of the design and mechanism of NKP-1339/miR-142-5p-NBs. The nanobubble system enables US-triggered codelivery of NKP-1339 and miR-142-5p to tumor cells. NKP-1339 induces ICD by disrupting mitochondrial function, elevating ROS, and triggering CRT externalization and HMGB1/ATP release. Concurrently, miR-142-5p down-regulates PD-L1 expression, reversing immune suppression. These combined effects facilitate CD8<sup>+</sup> T cell activation and potentiate antitumor immune responses in esophageal squamous cell carcinoma. DRP1, dynamin-related protein 1; OPA1, optic atrophy 1; PGC1-α, peroxisome proliferator-activated receptor gamma coactivator 1-alpha; MHC I, major histocompatibility complex I; TCR, T cell receptor; CD80, cluster of differentiation 80; CD86, cluster of differentiation 86; CD28, cluster of differentiation 28; PD-1, programmed cell death protein 1; Cytotoxic CD8<sup>+</sup>, cytotoxic CD8<sup>+</sup> T cells; IFN-γ, interferon gamma; TNF-α, tumor necrosis factor-alpha.</p></figcaption></figure></section><section id="sec2"><h2 class="pmc_sec_title">Materials and Methods</h2>
<section id="sec3"><h3 class="pmc_sec_title">Materials and reagents</h3>
<p>The following materials and reagents were used: 1,2-Dipalmitoyl-sn-glycero-3-phosphocholine (DPPC; Avanti Polar Lipids, USA); polyethylene glycol 2000 (PEG2000; Avanti Polar Lipids, USA); 3β-[N-(N′,N′-dimethylaminoethane)-carbamoyl]cholesterol (DC-chol; Avanti Polar Lipids, USA); NKP-1339 (MedChemExpress USA; 197723-00-5); Lipomaster 2000 (Vazyme, TL201); TUNEL Assay Kit (Hoffman-LaRoche Ltd, Basel, Switzerland); Fluo-4 AM Dye (Thermo Fisher Scientific, USA); DCFH-DA Dye (Beyotime, China); Annexin V-FITC (fluorescein isothiocyanate)/PI (propidium iodide) Double Staining Kit (BD Biosciences, USA); and MitoTracker® Red (USA).</p></section><section id="sec4"><h3 class="pmc_sec_title">Experimental methods</h3>
<section id="sec5"><h4 class="pmc_sec_title">Cell and animal models</h4>
<p>Male C57BL/6 mice (6 to 8 weeks,18 to 20 g) were purchased from the Wuhan Institute of Biological Products. All mice were housed under specific pathogen-free (SPF) conditions at the Animal Experiment Center of China Three Gorges University. Animal experiments were approved by the Animal Experiment Committee of China Three Gorges University (ethical approval number: 2023120A) and were conducted following the guidelines of the Ministry of Science and Technology of the People’s Republic of China. The mouse esophageal squamous carcinoma Mec25 cell line was provided by the School of Medicine, Shenzhen University, and the International Cancer Center. The culture medium consisted of Dulbecco’s Modified Eagle Medium (DMEM) (Gibco, USA) supplemented with 10% fetal bovine serum (Gibco, USA) and 1% penicillin/streptomycin (Solarbio, Beijing, China), and cells were cultured at 37 °C with 5% CO₂.</p></section></section><section id="sec6"><h3 class="pmc_sec_title">Preparation and characterization of ultrasound nanobubbles</h3>
<p>Different types of nanobubbles (NBs) were prepared using the thin-film hydration and mechanical agitation methods. Empty NBs were prepared by mixing DPPC, DSPE-PEG2000, and DC-chol in a 5:2:0.5 mass ratio and dissolved in chloroform and rotary-evaporated at 42 °C for 1 h to form a lipid film. Phosphate-buffered saline (PBS)/glycerol (9:1) was then added, and the mixture was dissolved at 45 °C. The resulting suspension was transferred into a vial, vacuumed, and filled with C<sub>3</sub>F<sub>8</sub> gas, and mechanically agitated for 90 s to yield a milky suspension of empty NBs. NKP-1339-NBs were prepared by adding NKP-1339 (mass ratio 5:2:0.5:0.25) to the above procedure. For miR-142-5p-NBs, the DC-chol ratio was increased to 5:2:2 to create cationic NBs, which were then incubated with miR-142-5p plasmid (1 μg: 25 μl) for 30 min. NKP-1339/miR-142-NBs were prepared by combining NKP-1339-NBs with the plasmid using the same method. All NBs were sterilized and stored at 4 °C for later use.</p>
<p>The morphology and structure of the prepared NKP-1339/miR-142-NBs were observed using transmission electron microscopy (TEM; Tecnai G2, Thermo Fisher Scientific, USA), and the particle size, distribution, and zeta potential were measured using a Zetasizer Nano ZS to evaluate dispersion and stability.</p></section><section id="sec7"><h3 class="pmc_sec_title">Drug encapsulation efficiency of ultrasound NBs</h3>
<p>The drug encapsulation efficiency of NKP-1339/miR-142-NBs was determined by ultraviolet–visible (UV–Vis) spectrophotometry and dialysis. Samples were placed in dialysis bags (Union Carbide, USA) and dialyzed in PBS for 6 h, with PBS being replaced every hour to remove free NKP-1339. After dialysis, the samples were mixed with methanol to release NKP-1339, and the absorbance at the maximum absorption wavelength of NKP-1339 (OD value) was measured. The NKP-1339 concentration was calculated using a standard curve. Encapsulation efficiency was calculated using the formula: Encapsulation efficiency (%) = (amount of NKP-1339 loaded/total NKP-1339 mass) × 100%. To verify the loading capacity of miR-142 plasmid, agarose gel electrophoresis was performed.</p></section><section id="sec8"><h3 class="pmc_sec_title">Establishment of animal models</h3>
<p>For the esophageal cancer xenograft model, mice received subcutaneous injections on the right flank with a suspension containing approximately 1 × 10<sup>8</sup> Mec25 cells. Once the tumor volume reached 100 mm<sup>3</sup>, the mice were randomly divided into 8 groups: (a) Control group (saline); (b) N-NBs+US group (blank NBs+US); (c) NKP-1339 group (NKP-1339 solution); (d) NKP-1339+US group (NKP-1339+US); (e) NKP-1339-NBs+US group (NKP-1339-loaded NBs+US); (f) miR-142-5p group (gene therapy); (g) miR-142-NBs+US group (miR-142-loaded NBs+US); and (h) NKP-1339/miR-142-NBs+US group (NKP-1339/miR-142 combined-loaded NBs+US). Mice received intravenous injections of the respective solution or NBs suspension every other day, for a total of 6 treatments. For the US groups, US treatment was administered immediately after the injection at the tumor site (1 MHz frequency, 1.5 W/cm<sup>2</sup> intensity, 50% duty cycle, 120 s). Tumor length (<em>L</em>) and width (<em>W</em>) were measured before each treatment, and tumor volume (<em>V</em>) was calculated using the formula <em>V</em> = (<em>A</em> × <em>B</em><sup>2</sup>)/2. Mouse body weight changes were recorded throughout the study. Upon completion of treatment, mice were euthanized, and spleen, major organs (heart, liver, spleen, lungs, and kidneys), and tumor samples were collected. Tumor weight was measured to calculate the tumor inhibition rate, and histological analyses were performed. All animal experiments were conducted with <em>n</em> = 6 mice per group.</p></section><section id="sec9"><h3 class="pmc_sec_title">Pharmacokinetic analysis of ultrasound NBs+US</h3>
<p>Tumor-bearing mice were divided into 3 groups: Free Dir, Dir-NBs, and Dir-NKP-1339/miR-142-NBs (3 mice per group). After intravenous injection of 200 μl of the respective solution, fluorescence images were captured at 0, 0.5, 1, 6, 12, and 24 h using the in vivo imaging system (IVIS) system (PerkinElmer, USA) with excitation at 754 nm and emission at 778 nm. Under anesthesia, whole-body fluorescence distribution was monitored to analyze the drug distribution and signal accumulation at the tumor site. Mice were euthanized at 24 h, and tumors and organs were collected to observe fluorescence signal distribution. Semiquantitative analysis was performed using ImageJ software to calculate the fluorescence intensity in tumors and organs, assessing the aggregation efficiency and distribution of Dir-NKP-1339/miR-142-NBs. Tumor-bearing mice were randomly assigned to 3 treatment groups: NBs, NKP-1339-NBs, and NKP-1339/miR-142-NBs. Each group received a 200-μl intravenous injection containing approximately 1 × 10<sup>9</sup> NBs. Real-time tumor-targeted contrast enhancement was monitored using contrast-enhanced ultrasound (CEUS) imaging (Mindray RESONA7S, equipped with a 14-MHz linear transducer). Imaging data were recorded at 0, 10, 45, 90, and 150 s postinjection. Mice were anesthetized with 2% isoflurane and maintained at a constant body temperature throughout the procedure. Quantitative analysis of signal intensity and decay kinetics was performed using Sonamath software to assess the targeting efficiency of each formulation.</p></section><section id="sec10"><h3 class="pmc_sec_title">H&amp;E staining</h3>
<p>The tumor tissues and various organs of the mice were embedded and fixed in paraffin, and tissue sections were prepared. After staining with hematoxylin and eosin (H&amp;E), morphological changes in the tumor tissues and organs were observed.</p></section><section id="sec11"><h3 class="pmc_sec_title">Immunohistochemistry</h3>
<p>After dewaxing and rehydration of the tumor sections (4 μm), antigen retrieval was performed using citrate buffer. Endogenous peroxidase activity was blocked with 3% H₂O₂ solution, followed by blocking with 5% bovine serum albumin (BSA) for 1 h. The sections were incubated overnight at 4 °C with primary antibodies: Bax (1:200, Santa Cruz, sc-20067) and Bcl-2 (1:200, Santa Cruz, sc-7382). After washing with PBS, the sections were incubated with a secondary antibody (goat anti-rabbit IgG, 1:500, Jackson ImmunoResearch) at room temperature for 1 h. Following DAB staining, nuclei were counterstained, and sections were mounted. Images were captured using an optical microscope, and semiquantitative analysis was performed using ImageJ software.</p></section><section id="sec12"><h3 class="pmc_sec_title">Immunofluorescence</h3>
<p>Tumor sections (4 μm) were dewaxed, rehydrated, and subjected to antigen retrieval, washed, and blocked before incubation with primary antibodies for 12 to 16 h: anti-PD-L1 (1:200, Proteintech, 66248-1-lg), anti-CRT (1:200, Proteintech, 27298-1-AP), anti-CD3 (1:400, Proteintech, 60181-1-Ig), anti-CD8 (1:400, Proteintech, 66868-1-Ig), anti-IFN-γ (1:200, Proteintech, 15365-1-AP), anti-CD80 (1:500, Proteintech, 66406-1-Ig), and anti-CD86 (1:100, Abcam, ab239075). After PBS washing, sections were incubated with fluorescence-conjugated secondary antibodies (1:500, Jackson ImmunoResearch) for 1 h. Cell apoptosis was detected using a TUNEL kit (Hoffman-LaRoche Ltd, Basel, Switzerland), and nuclei were stained with DAPI (4′,6-diamidino-2-phenylindole) before mounting. Images were observed using a laser confocal microscope, and semiquantitative analysis of fluorescence intensity was performed using ImageJ software.</p></section><section id="sec13"><h3 class="pmc_sec_title">Western blotting</h3>
<p>Total proteins were extracted from tumor tissues or cells using radioimmunopreciptation assay lysis buffer (Solarbio, China) and protein concentration was determined using a bicinchoninic acidkit (Servicebio, China). Proteins were mixed with loading buffer, denatured by boiling at 95 °C for 10 min, and separated by sodium dodecyl sulfate–polyacrylamide gel electrophoresis (10% separating gel). The proteins were transferred to a polyvinylidene difluoride membrane (Millipore, USA). The membrane was blocked with 5% skimmed milk for 1 h and incubated with primary antibodies overnight at 4 °C: PD-L1 (1:5,000, Proteintech, 66248-1-lg), CRT (1:1,000, Proteintech, 27298-1-AP), HMGB1 (1:3,000, Proteintech, 66525-1-Ig), heat shock protein 70 (HSP70) (1:10,000, Proteintech, 10995-1-AP), heat shock protein 90 (HSP90) (1:8,000, Proteintech, 13171-1-AP), DRP1 (1:5,000, Proteintech, 12957-1-AP), OPA1 (1:500, Santa Cruz, sc-393296), PGC1-α (1:2,500, ABclonal, A20995), cyclophilin B (1:1,000, Proteintech, 11607-1-AP), and β-actin (1:1,000, Proteintech, 60008-1-Ig). After washing 3 times with TBST, the membrane was incubated with horseradish peroxidase-conjugated secondary antibody (1:5,000, Proteintech) for 1 h at room temperature and washed 3 times. Protein bands were detected using ECL chemiluminescent reagent (Pierce, USA), and signals were captured using a Bio-Rad gel imaging system (Bio-Rad, USA). Semiquantitative analysis was performed using ImageJ software.</p></section><section id="sec14"><h3 class="pmc_sec_title">Reverse transcription-quantitative PCR</h3>
<p>Total RNA was extracted from fresh tumor tissues using the Trizol reagent (TaKaRa, Japan) and reverse transcribed to cDNA using the PrimeScript RT kit (TaKaRa, Japan). Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) was performed using SYBR Premix Ex Taq II (TaKaRa, Japan) on an Applied Biosystems 7900HT system with the following thermal cycling parameters: 95 °C for 30 s, followed by 40 cycles of 95 °C for 5 s and 60 °C for 30 s. Actin and U6 were used as reference genes, and relative expression levels were calculated using the 2<sup>−ΔΔCt</sup> method. The experiment was performed in triplicate to ensure reliability, and primer sequences are provided in Table <a href="#supplementary-material-1" class="usa-link">S1</a>.</p></section><section id="sec15"><h3 class="pmc_sec_title">miRNA transfection</h3>
<p>A total of 1.5 × 10<sup>5</sup> Mec25 esophageal cancer cells were seeded into 6-well plates and cultured until they adhered to the surface. The transfection conditions for the miRNA were optimized based on the manufacturer’s instructions and preliminary experiments. A total of 25 μl of Opti-MEM medium was added to 2 tubes: one containing 1.5 μl of Lipomaster 2000 (Vazyme, TL201) and the other containing 0.5 μg of the corresponding miRNA plasmid (GV268, GV268-miR-142-5p, miR mimic NC, miR-142-5p mimic, miR inhibitor NC, and miR-142-5p inhibitor). After mixing the components, the solution was allowed to stand for 5 min to form the transfection complex. The culture medium was removed, and the cells were washed twice with PBS. The complex was then added, and the mixture was gently mixed. After 6 h of transfection, the medium was replaced, and the cells were incubated for an additional 24 to 48 h before being collected for subsequent experiments.</p></section><section id="sec16"><h3 class="pmc_sec_title">ROS and mitochondrial detection</h3>
<p>A total of 1 × 10<sup>4</sup> cells were seeded into 24-well plates and incubated overnight at 37 °C with 5% CO₂. The following day, drugs were added, and cells were subjected to US irradiation (1.5 MHz, 45 s, and 50% duty cycle). After incubation for 5 h, the cells were washed 3 times with PBS. To detect reactive oxygen species (ROS), 200 μl of 10 μmol/l DCFH-DA fluorescence probe (Beyotime, Shanghai) was added, and the cells were incubated in the dark for 30 min. After washing with PBS, 500 μl of serum-free DMEM was added, and fluorescence images were acquired using an inverted fluorescence microscope (excitation wavelength, 488 nm; emission wavelength, 525 nm). ImageJ software was used for semiquantitative analysis. In addition, mitochondria were stained with MitoTracker Red (final concentration, 50 to 200 nM, Invitrogen, USA), and after washing with PBS, the dye working solution was added and incubated at 37 °C in the dark for 15 to 30 min. Following 3 PBS washes to remove excess dye, fluorescence signals were detected using a laser scanning confocal microscope (Nikon Eclipse Ti, Japan), and fluorescence intensity and mitochondrial morphology were analyzed.</p></section><section id="sec17"><h3 class="pmc_sec_title">Flow cytometry</h3>
<p>Mec25 cells were seeded in 6-well plates and subjected to different treatments for 48 h. The following assays were performed: Calcium ion detection: Cells were stained with Fluo-4 AM dye (final concentration, 5 μM) and incubated at 37 °C in the dark for 30 min. After 3 washes with PBS, single-cell suspensions were prepared, and calcium ion fluorescence intensity was measured using a flow cytometer (BD FACSVerse, USA). ROS detection: Cells were stained with 10 μM DCFH-DA dye (Beyotime, China) and incubated at 37 °C in the dark for 30 min. After washing with PBS, single-cell suspensions were collected and ROS levels were assessed using a flow cytometer (excitation wavelength, 488 nm; emission wavelength, 525 nm). Cell apoptosis analysis: Cells were stained using an Annexin V-FITC/PI dual staining kit (BD Biosciences, USA), and apoptosis was analyzed by detecting FITC and PI fluorescence signals with a flow cytometer. The apoptosis rate was then analyzed using FlowJo software. PD-L1 and CRT protein expression detection: After 3 PBS washes, cells were stained with anti-PD-L1 antibody (1:200, Proteintech, FITC-65081) and anti-CRT antibody (1:200, Proteintech, 27298-1-AP). In addition, isolated and treated splenocytes were stained with phycoerythrin-conjugated anti-mouse NK1.1 antibody (BioLegend), FITC-conjugated anti-CD3 antibody, and allophycocyanin-conjugated anti-CD8 antibody (BioLegend). After 30 min of incubation at room temperature in the dark, cells were washed 3 times with PBS. PD-L1 and CRT expression levels were analyzed using a flow cytometer, and the data were further analyzed with FlowJo software.</p></section><section id="sec18"><h3 class="pmc_sec_title">LDH release assay</h3>
<p>For natural killer (NK) cell killing activity detection, splenocytes were cocultured with Mec25 esophageal cancer cells at effector-to-target ratios (E:T) of 100:1, 50:1, and 25:1 for 4 h. Cell cytotoxicity was measured using a lactate dehydrogenase (LDH) cytotoxicity assay kit (Beyotime, Shanghai), and the cytotoxicity was calculated using the formula: Cytotoxicity (%) = [(experimental release OD − spontaneous release OD)/(maximum release OD − spontaneous release OD)] × 100%. In the CTL killing activity assay, splenocytes were incubated with Mec25 cell lysates for 48 h and then cocultured with Mec25 cells at an E:T ratio of 100:20 for 4 h. LDH cytotoxicity was measured as described above.</p></section><section id="sec19"><h3 class="pmc_sec_title">Statistical analysis</h3>
<p>All experimental data were analyzed using SPSS 19.0 and GraphPad Prism 8.0. Results are presented as mean ± standard error of the mean (SEM). Group comparisons used Student’s <em>t</em> test, with statistical significance set at <em>P</em> &lt; 0.05, <em>P</em> &lt; 0.01, and <em>P</em> &lt; 0.001. All experiments were repeated at least 3 times to ensure accuracy and reproducibility.</p></section></section><section id="sec20"><h2 class="pmc_sec_title">Results</h2>
<section id="sec21"><h3 class="pmc_sec_title">Preparation and characterization of US NBs</h3>
<p>NKP-1339/miR-142-NBs were synthesized by thin-film hydration and mechanical oscillation. Transmission electron microscopy revealed that the NBs were spherical with a uniform size distribution and smooth outer membranes (Fig. <a href="#F2" class="usa-link">2</a>A and B). The particle size and zeta potential of NKP-1339/miR-142-NBs are shown in Fig. <a href="#F2" class="usa-link">2</a>C and D. The results showed that the average particle sizes of NBs, NKP-1339-NBs, and NKP-1339/miR-142-NBs were 264.23 ± 17.39, 343.93 ± 27.32, and 374.87 ± 23.23 nm, respectively (Fig. <a href="#F2" class="usa-link">2</a>E). The average zeta potentials were 11.8 ± 0.99, 11.0 ± 0.819, and 7.82 ± 0.406 mV (Fig. <a href="#F2" class="usa-link">2</a>F), and the polydispersity indices (PDIs) were 0.200 ± 0.026, 0.179 ± 0.0096, and 0.140 ± 0.022, indicating good dispersion and stability (Fig. <a href="#F2" class="usa-link">2</a>G). The UV–Vis absorption spectrum of NKP-1339/miR-142-NBs closely resembled that of free NKP-1339, suggesting that the NKP-1339 chromophore remained unchanged upon encapsulation (Fig. <a href="#F2" class="usa-link">2</a>H). NBs loaded with PI-miR-142 plasmid exhibited red fluorescence on their surface (Fig. <a href="#F2" class="usa-link">2</a>I). Using the membrane dialysis method, the encapsulation efficiency of NKP-1339 in NKP-1339/miR-142-NBs was determined to be 45.38% ± 3.01%. As shown in the gel electrophoresis results, no visible band appeared when the nanobubble (NB) volume reached 25 μl, indicating that 1 μg of miR-142 plasmid represented the maximum DNA loading capacity for 25 μl of NBs (Fig. <a href="#F2" class="usa-link">2</a>J). These findings confirmed the morphology, particle size, surface charge, and plasmid loading efficiency of NKP-1339/miR-142-NBs, demonstrating their stability and loading capacity at the nanoscale. Therefore, NBs may serve as an effective delivery system for NKP-1339 and miR-142-5p.</p>
<figure class="fig xbox font-sm" id="F2"><h4 class="obj_head">Fig. 2.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><img class="graphic" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3dd3/12334082/8dad4ade276d/bmr.0232.fig.002.jpg" loading="lazy" height="660" width="565" alt="Fig. 2."></p>
<div class="p text-right font-secondary"><a href="figure/F2/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Preparation and characterization of NKP-1339/miR-142 NBs. (A) Morphology of NKP-1339/miR-142-NBs observed by optical microscopy (scale bar = 10 μm). (B) Morphological features of NBs were observed using transmission electron microscopy (80,000× magnification, scale bar = 200 nm). (C) Particle size distribution of NKP-1339/miR-142-NBs. (D) Zeta potential analysis of the surface charge of the NBs. (E) Particle size analysis of various modified nanobubble groups. (F) Zeta potential analysis of various modified nanobubble groups. (G) Polydispersity index (PDI) analysis of various modified nanobubble groups. (H) UV–Vis absorption spectra of NKP-1339/miR-142-NBs and free NKP-1339 showing no significant changes. (I) Red fluorescence of propidium iodide-stained miR-142 plasmid (PI-miR-142) on the surface of miR-142-NBs was observed using fluorescence microscopy (magnification 200×, scale bar = 10 μm). (J) Agarose gel electrophoresis confirming the loading capacity of the NBs for miR-142 plasmid.</p></figcaption></figure></section><section id="sec22"><h3 class="pmc_sec_title">Pharmacokinetics and tissue distribution of US NBs: Prolonged circulation time and increased accumulation in tumor</h3>
<p>To investigate the pharmacokinetic characteristics and tissue distribution of NKP-1339/miR-142-NBs combined with US treatment in tumor-bearing mice, the fluorescence distribution in different groups (Free-Dir, Dir-NBs, and Dir-NKP-1339/miR-142-NBs) was monitored in real-time using a small-animal imaging system. This was performed to verify whether the NBs could extend the circulation time of the drug and enhance its tumor-targeting accumulation. In vivo imaging showed a gradual increase in the fluorescence signal in tumor tissues, especially in the Dir-NKP-1339/miR-142-NBs group, which exhibited a considerably higher fluorescence intensity than the other groups. Six hours after injection, the fluorescence signal in the Free-Dir group notably decreased, while signals in the Dir-NBs and Dir-NKP-1339/miR-142-NBs groups persisted, with the latter group maintaining a high fluorescence level at the tumor site even after 24 h (Fig. <a href="#F3" class="usa-link">3</a>A and B), indicating that the NBs markedly enhanced drug accumulation in the tumor, with the Dir-NKP-1339/miR-142-NBs combination showing the best targeting effect.</p>
<figure class="fig xbox font-sm" id="F3"><h4 class="obj_head">Fig. 3.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><img class="graphic" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3dd3/12334082/7b8ccaccdbd4/bmr.0232.fig.003.jpg" loading="lazy" height="660" width="613" alt="Fig. 3."></p>
<div class="p text-right font-secondary"><a href="figure/F3/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Pharmacokinetic analysis and tissue distribution of NKP-1339/miR-142-NBs+US. (A) Fluorescence distribution in tumor-bearing mice of different groups (Free-Dir, Dir-NBs, and Dir-NKP-1339/miR-142-NBs+US) was detected by the in vivo imaging system (IVIS). (B) Quantitative analysis of tissue fluorescence intensity from panel (A). (C) Fluorescence imaging of organs at 24 h postinjection for each group. (D) Quantitative analysis of tumor and organ fluorescence intensity from panel (C). (E) Contrast-enhanced US imaging results showing that NKP-1339/miR-142-NBs+US enhanced imaging and in vivo targeted detection. (F) Quantitative analysis of peak intensity in tumor regions for different groups. *<em>P</em> &lt; 0.05, **<em>P</em> &lt; 0.01.</p></figcaption></figure><p>Organ imaging results revealed that fluorescence in the Free-Dir group was primarily concentrated in the tumor, followed by the liver and kidneys, suggesting that the drug might be cleared via hepatic and renal metabolism (Fig. <a href="#F3" class="usa-link">3</a>C). In contrast, fluorescence intensity in the tumor tissue of the Dir-NBs and Dir-NKP-1339/miR-142-NBs groups was appreciably higher, being 4.36 and 5.54 times that of the free-Dir group, respectively (Fig. <a href="#F3" class="usa-link">3</a>D), further confirming that US NBs can enhance drug targeting and tumor accumulation. To observe the retention and imaging properties of the NBs in vivo, CEUS was performed to monitor the distribution of the contrast agent within the tumor tissue. The results indicated that all 3 types of NBs exhibited good imaging capabilities (Fig. <a href="#F3" class="usa-link">3</a>E). At 150 s postinjection, the contrast agent in the NBs group almost disappeared from the tumor, whereas in the NKP-1339-NBs and NKP-1339/miR-142-NBs groups, the contrast agent signals remained with fluorescence intensities 1.63 and 1.71 times that of the N-NB group, respectively (Fig. <a href="#F3" class="usa-link">3</a>E and F). This suggests that US-targeted NBs can specifically accumulate at the tumor site and effectively prolong the drug retention time, further enhancing drug targeting and delivery efficiency.</p>
<p>The pharmacokinetic and tissue distribution results of this study demonstrate that NKP-1339/miR-142-NBs not only extend the drug’s circulation time but also markedly increase its tumor-targeting accumulation, while reducing nonspecific distribution in healthy tissues. This targeted enhancement and prolonged retention mechanism further validates the potential of NBs in tumor therapy.</p></section><section id="sec23"><h3 class="pmc_sec_title">Antitumor effects of NKP-1339/miR-142-NBs combined with US</h3>
<section id="sec24"><h4 class="pmc_sec_title">Tumor-suppressive effect of NKP-1339/miR-142-NBs</h4>
<p>The antitumor effects of NKP-1339/miR-142-NBs combined with US therapy were evaluated in an esophageal cancer tumor-bearing mouse model (<em>n</em> = 6 per group). The treatment protocol is outlined in Fig. <a href="#F4" class="usa-link">4</a>A, and tumor growth and growth curves are presented in Fig. <a href="#F4" class="usa-link">4</a>B and C. The experimental results demonstrated that the control group exhibited rapid tumor growth, whereas all treatment groups showed remarkably inhibited tumor volume and mass, with the NKP-1339/miR-142-NBs+US group showing the most pronounced antitumor effect.</p>
<figure class="fig xbox font-sm" id="F4"><h5 class="obj_head">Fig. 4.</h5>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><img class="graphic" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3dd3/12334082/ec32c7c1b4ac/bmr.0232.fig.004.jpg" loading="lazy" height="604" width="660" alt="Fig. 4."></p>
<div class="p text-right font-secondary"><a href="figure/F4/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>In vivo experiment on the anticancer effect of NKP-1339/miR-142-NBs combined with US treatment in esophageal cancer subcutaneous xenografts of mice. (<em>n</em> = 6 per group). (A) Schematic diagram of the in vivo treatment protocol for esophageal cancer-bearing mice. (B) Comparison of tumor sizes in mice from each group. (C) Tumor growth curves for mice in each group. (D) Changes in body weight of mice in each group.</p></figcaption></figure><p>In addition, the tumor volume increased over time, with the saline control group showing the fastest growth. Tumor inhibition rates revealed that the NKP-1339 and NKP-1339+US groups had remarkably higher tumor volume inhibition rates (<em>P</em> &lt; 0.01). Notably, the NKP-1339-NBs+US group achieved a volume inhibition rate of 50.65% ± 4.54%, considerably outperforming the drug-only and US-only groups (<em>P</em> &lt; 0.01), while the NKP-1339/miR-142-NBs+US group displayed the highest volume inhibition rate of 60.37% ± 6.77% (<em>P</em> &lt; 0.01). Tumor weight analysis also indicated a reduction in tumor mass in all treatment groups compared with that in the control group. The NKP-1339-NBs+US and NKP-1339/miR-142-NBs+US groups showed the most significant tumor mass inhibition rates of 67.65% ± 1.36% and 79.72% ± 0.1%, respectively (<a href="#T1" class="usa-link">Table</a>). Furthermore, the mouse body weight data showed that the control and N-NBs+US groups showed a gradual decrease in weight gain, whereas the other treatment groups exhibited an increased weight gain rate (Fig. <a href="#F4" class="usa-link">4</a>D). In conclusion, the NKP-1339/miR-142-NBs combined with US treatment demonstrated a synergistic antitumor effect, with the NKP-1339/miR-142-NBs+US group showing the most significant therapeutic effect and offering a potential new strategy for esophageal cancer treatment.</p>
<section class="tw xbox font-sm" id="T1"><h5 class="obj_head">Table.</h5>
<div class="caption p"><p>The tumor inhibition rate of tumor volume and weight in each group</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<thead><tr>
<th align="left" rowspan="1" colspan="1">Groups</th>
<th align="center" rowspan="1" colspan="1">Tumor volume (mm<sup>3</sup>)</th>
<th align="center" rowspan="1" colspan="1">Tumor weight (g)</th>
<th align="center" rowspan="1" colspan="1">Volume inhibition rate (%)</th>
<th align="center" rowspan="1" colspan="1">Weight inhibition rate (%)</th>
</tr></thead>
<tbody>
<tr>
<td align="left" rowspan="1" colspan="1">Control</td>
<td align="center" rowspan="1" colspan="1">1,876.67 ± 24.94</td>
<td align="center" rowspan="1" colspan="1">3.53 ± 0.13</td>
<td align="center" rowspan="1" colspan="1">0</td>
<td align="center" rowspan="1" colspan="1">0</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">N-NBs+US</td>
<td align="center" rowspan="1" colspan="1">1,703.67 ± 56.45</td>
<td align="center" rowspan="1" colspan="1">2.68 ± 0.16</td>
<td align="center" rowspan="1" colspan="1">7.42 ± 2.77<a href="#T1FN1" class="usa-link"><sup>*</sup></a>
</td>
<td align="center" rowspan="1" colspan="1">18.79 ± 1.29<a href="#T1FN1" class="usa-link"><sup>*</sup></a>
</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">NKP-1339</td>
<td align="center" rowspan="1" colspan="1">1,366.67 ± 96.09</td>
<td align="center" rowspan="1" colspan="1">1.79 ± 0.11</td>
<td align="center" rowspan="1" colspan="1">32.39 ± 2.08<a href="#T1FN2" class="usa-link"><sup>**</sup></a>
</td>
<td align="center" rowspan="1" colspan="1">49.37 ± 1.19<a href="#T1FN2" class="usa-link"><sup>**</sup></a>
</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">NKP-1339-NBs</td>
<td align="center" rowspan="1" colspan="1">1,185 ± 139.37</td>
<td align="center" rowspan="1" colspan="1">1.54 ± 0.08</td>
<td align="center" rowspan="1" colspan="1">43.07 ± 4.84<a href="#T1FN2" class="usa-link"><sup>**</sup></a>
</td>
<td align="center" rowspan="1" colspan="1">56.52 ± 1.25<a href="#T1FN2" class="usa-link"><sup>**</sup></a>
</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">NKP-1339-NBs+US</td>
<td align="center" rowspan="1" colspan="1">926.67 ± 113.8</td>
<td align="center" rowspan="1" colspan="1">1.14 ± 0.08</td>
<td align="center" rowspan="1" colspan="1">50.65 ± 4.54<a href="#T1FN2" class="usa-link"><sup>**</sup></a>
</td>
<td align="center" rowspan="1" colspan="1">67.65 ± 1.36<a href="#T1FN2" class="usa-link"><sup>**</sup></a>
</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">miR-142-5p</td>
<td align="center" rowspan="1" colspan="1">1,647.33 ± 145.05</td>
<td align="center" rowspan="1" colspan="1">2.14 ± 0.06</td>
<td align="center" rowspan="1" colspan="1">19.81 ± 1.12<a href="#T1FN2" class="usa-link"><sup>**</sup></a>
</td>
<td align="center" rowspan="1" colspan="1">39.42 ± 1.14<a href="#T1FN2" class="usa-link"><sup>**</sup></a>
</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">miR-142-NBs+US</td>
<td align="center" rowspan="1" colspan="1">1,447.67 ± 55.19</td>
<td align="center" rowspan="1" colspan="1">1.93 ± 0.04</td>
<td align="center" rowspan="1" colspan="1">24.63 ± 2.3<a href="#T1FN2" class="usa-link"><sup>**</sup></a>
</td>
<td align="center" rowspan="1" colspan="1">45.26 ± 0.89<a href="#T1FN2" class="usa-link"><sup>**</sup></a>
</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">miR-142/NKP-1339-NBs+US</td>
<td align="center" rowspan="1" colspan="1">745 ± 167.1</td>
<td align="center" rowspan="1" colspan="1">0.71 ± 0.03</td>
<td align="center" rowspan="1" colspan="1">60.37 ± 6.77<a href="#T1FN2" class="usa-link"><sup>**</sup></a>
</td>
<td align="center" rowspan="1" colspan="1">79.72 ± 0.1<a href="#T1FN2" class="usa-link"><sup>**</sup></a>
</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/T1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p">
<div class="fn" id="T1FN1">
<sup>*</sup><p class="display-inline"><em>P</em> &lt; 0.05 vs. control group.</p>
</div>
<div class="fn" id="T1FN2">
<sup>**</sup><p class="display-inline"><em>P</em> &lt; 0.01 vs. control group.</p>
</div>
</div></section></section><section id="sec25"><h4 class="pmc_sec_title">NKP-1339/miR-142-NBs+US induces apoptosis in esophageal cancer cells</h4>
<p>To evaluate the apoptotic effects of NKP-1339/miR-142-NBs combined with US treatment on tumor cells, H&amp;E staining was performed to assess pathological changes in tumor tissues, and the TUNEL assay was employed to measure apoptosis levels in tumor cells. H&amp;E staining showed varying degrees of cellular degeneration and necrosis across all treatment groups, with the NKP-1339/miR-142-NBs+US group exhibiting the most pronounced pathological changes (Fig. <a href="#supplementary-material-1" class="usa-link">S1</a>A). In the control group, the tumor cells were highly proliferative, characterized by enlarged and intensely stained nuclei, a considerably increased nuclear-to-cytoplasmic ratio, and notable cellular atypia. Compared with the control group, the NKP-1339 group showed a significant increase in the proportion of apoptotic cells. Furthermore, the apoptosis levels in the NKP-1339-NBs+US group were higher than those in the NKP-1339+US and N-NBs+US groups (<em>P</em> &lt; 0.05, Fig. <a href="#supplementary-material-1" class="usa-link">S1</a>B and E). Notably, the NKP-1339/miR-142-NBs+US group demonstrated the highest levels of apoptosis, which were higher than those in the miR-142-5p, miR-142-NBs+US, and NKP-1339-NBs+US groups (<em>P</em> &lt; 0.05). Flow cytometry results further confirmed that compared with the control group, the NKP-1339 group had a higher proportion of apoptotic cells. The apoptosis rate in the NKP-1339-NBs+US group was 12.82%, which was higher than those in the NKP-1339+US and N-NBs+US groups (<em>P</em> &lt; 0.01). The NKP-1339/miR-142-NBs+US group had an apoptosis rate of 15.09%, surpassing that of the miR-142-NBs+US and NKP-1339-NBs+US groups (<em>P</em> &lt; 0.05, Fig. <a href="#supplementary-material-1" class="usa-link">S1</a>D and H).</p>
<p>To further investigate the role of NKP-1339/miR-142-NBs+US combination therapy in the apoptotic mechanism, immunohistochemistry was performed to detect the expression of the apoptosis-related proteins Bax and Bcl-2. Bax and Bcl-2 proteins promote and inhibit programmed cell death, respectively, and play pivotal roles in regulating apoptosis. Compared with that in the control group, Bax protein expression was appreciably up-regulated in the NKP-1339 group, and Bax levels in the NKP-1339-NBs+US group were higher than those in the NKP-1339+US and N-NBs+US groups (Fig. <a href="#supplementary-material-1" class="usa-link">S1</a>C and F). Notably, the NKP-1339/miR-142-NBs+US group exhibited the highest Bax protein expression across all treatment groups (<em>P</em> &lt; 0.05, Fig. <a href="#supplementary-material-1" class="usa-link">S1</a>F). In contrast, Bcl-2 protein expression decreased in all groups, showing a negative correlation with Bax expression (Fig. <a href="#supplementary-material-1" class="usa-link">S1</a>C and G). Moreover, Western blot (WB) and qPCR results further confirmed the expression patterns of Bax and Bcl-2, which were consistent with the immunohistochemical findings (Fig. <a href="#supplementary-material-1" class="usa-link">S1</a>I to M).</p>
<p>These results suggested that NKP-1339/miR-142-NBs combined with US therapy appreciably promoted tumor cell apoptosis. The underlying mechanism may involve the up-regulation of Bax expression and the down-regulation of Bcl-2 expression, which appears to be closely linked to the mitochondrial damage-induced apoptotic pathway.</p></section></section><section id="sec26"><h3 class="pmc_sec_title">NKP-1339/miR-142-NBs+US induced antitumor immune responses</h3>
<section id="sec27"><h4 class="pmc_sec_title">Verification of miR-142-5p targeting PD-L1</h4>
<p>To explore the regulatory effect of miR-142-5p on PD-L1 protein expression, plasmids GV268, GV268-miR-142-5p, and synthetic oligonucleotides (miR mimic NC, miR-142-5p mimic, miR inhibitor NC, and miR-142-5p inhibitor) of equal concentrations were transfected into esophageal cancer cells. After 48 h, the cells were collected, and PD-L1 protein levels were detected using WB. The results showed that compared with that in the GV268-transfected group, PD-L1 protein expression was substantially reduced following miR-142-5p transfection. Similarly, compared with the miR mimic NC group, transfection with the miR-142-5p mimic led to the down-regulation of PD-L1 protein expression. However, transfection with the miR-142-5p inhibitor resulted in considerably higher PD-L1 expression than that in the miR inhibitor NC group (Fig. <a href="#supplementary-material-1" class="usa-link">S2</a>B and C). These findings suggest that miR-142-5p and its mimic suppress PD-L1 protein expression, whereas its inhibitor promotes PD-L1 expression. Further validation by qPCR confirmed that miR-142-5p substantially reduced PD-L1 mRNA levels, which was consistent with the trend in protein expression (Fig. <a href="#supplementary-material-1" class="usa-link">S2</a>D and E).</p>
<p>Flow cytometry confirmed that miR-142-5p considerably suppressed the surface expression of PD-L1, whereas its inhibitor promoted PD-L1 expression (Fig. <a href="#supplementary-material-1" class="usa-link">S2</a>F and G). In vivo experiments showed that both miR-142-5p-NBs+US and NKP-1339/miR-142-NBs+US treatments considerably reduced PD-L1 expression in tumor tissues (Fig. <a href="#supplementary-material-1" class="usa-link">S2</a>H), consistent with the WB and qPCR results (Fig. <a href="#supplementary-material-1" class="usa-link">S2</a>I to L). In summary, miR-142-5p down-regulated PD-L1 expression by targeting and inhibiting its expression, thereby potentially exerting a significant antitumor effect. This mechanism was validated by both in vitro and in vivo experiments.</p></section><section id="sec28"><h4 class="pmc_sec_title">NKP-1339/miR-142-NBs increased CTL responses</h4>
<p>To further investigate the antitumor activity of immune checkpoint inhibitors combined with drugs, and to assess the antitumor immune activity of immune checkpoint blockade, flow cytometry was used to evaluate the proliferative capacity of splenic lymphocytes from mice. Splenic lymphocytes were labeled with a carboxyfluorescein diacetate succinimidyl ester fluorescent probe, which was evenly distributed among the progeny cells as they divided, with a gradual reduction in the fluorescence intensity. Subsequently, flow cytometry was performed to assess lymphocyte proliferation in each group.</p>
<p>Compared with that in the control group, the proliferative activity of lymphocytes in the NKP-1339 group showed an increasing trend, whereas the cell proliferation index in the NKP-1339-NBs+US group was higher than that in the NKP-1339+US and N-NBs+US groups (<em>P</em> &lt; 0.05, Fig. <a href="#F5" class="usa-link">5</a>A and B). Notably, the NKP-1339/miR-142-NBs+US group exhibited the highest in vitro proliferation index, which was approximately 7 times that of the control group and 1.5 times that of the NKP-1339-NBs+US group (<em>P</em> &lt; 0.05), and was superior to those of the miR-142-NBs+US group and other single-treatment groups. These results suggest that NKP-1339/miR-142-NBs combination treatment can enhance the proliferative capacity of mouse lymphocytes.</p>
<figure class="fig xbox font-sm" id="F5"><h5 class="obj_head">Fig. 5.</h5>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><img class="graphic" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3dd3/12334082/e1c7991a209d/bmr.0232.fig.005.jpg" loading="lazy" height="660" width="482" alt="Fig. 5."></p>
<div class="p text-right font-secondary"><a href="figure/F5/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Mechanism on immune response of NK cell and macrophage induced by NKP-1339/miR-142-NBs combined with US treatment. (A and B) Flow cytometry analysis of the in vitro proliferation activity and proliferation index of splenic lymphocytes in each group. (C and D) Flow cytometry analysis of the proportion of CTL cells in each group and quantitative analysis. (E) Lactate dehydrogenase (LDH) release assay to evaluate the cytotoxic activity of CTL cells in vitro. (F to K) Immunofluorescence analysis of tumor tissue for the infiltration of CD3<sup>+</sup> T CD8<sup>+</sup> T cells and the expression of IFN-γ, along with semiquantitative analysis (200×, scale bar = 100 μm). (L and M) mRNA expression of TNF-α and IFN-γ in tumor tissues. *<em>P</em> &lt; 0.05, **<em>P</em> &lt; 0.01, ***<em>P</em> &lt; 0.001.</p></figcaption></figure><p>Further analysis of the proportion of CD3<sup>+</sup> CD8<sup>+</sup> T cells revealed a trend consistent with the proliferation index. The proportion of CTLs in the NKP-1339-NBs+US group was higher than that in the N-NBs+US and NKP-1339+US groups (<em>P</em> &lt; 0.05). The NKP-1339/miR-142-NBs+US group had the highest proportion of CD3<sup>+</sup> CD8<sup>+</sup> T cells (15.64 %) (<em>P</em> &lt; 0.05, Fig. <a href="#F5" class="usa-link">5</a>C and D). Further evaluation of the CTL killing ability through the LDH release assay showed that, compared with that of tumor cells cocultured with CTLs, the killing rate of target cells was higher in the NKP-1339-NBs+US group, whereas the NKP-1339/miR-142-NBs+US group reached the maximum value, which was consistent with the changes in the proportion of CD8<sup>+</sup> T cells (Fig. <a href="#F5" class="usa-link">5</a>E).</p>
<p>To verify the T cell-mediated immune response in the TME, immunofluorescence staining was used to detect the protein expression levels of CD3<sup>+</sup> CD8<sup>+</sup> lymphocytes and IFN-γ in tumor tissues. As shown in Fig. <a href="#F5" class="usa-link">5</a>F to K, the expression of CD3<sup>+</sup>, CD8<sup>+</sup>, and IFN-γ in the NKP-1339 group was higher than in the control group (<em>P</em> &lt; 0.001). Furthermore, the expression of CD3<sup>+</sup>, CD8<sup>+</sup>, and IFN-γ in the NKP-1339-NBs+US group was further enhanced compared with that in the N-NBs+US and NKP-1339+US groups (<em>P</em> &lt; 0.05). The NKP-1339/miR-142-NBs+US group exhibited the highest levels of CD3<sup>+</sup>, CD8<sup>+</sup>, and IFN-γ expression, considerably higher than in all other groups (Fig. <a href="#F5" class="usa-link">5</a>F to K). These results were consistent with the trends observed in the flow cytometry and LDH release assays.</p>
<p>Activation of cellular immunity can subsequently increase cytokine production, and the up-regulation of IFN-γ and TNF-α expression can trigger the maturation of DCs. Therefore, TNF-α and IFN-γ, which are crucial for immune cell activation, were investigated. RT-qPCR analysis revealed that mRNA expression levels of TNF-α and IFN-γ were consistent with their respective protein expression trends. The NKP-1339/miR-142-NBs+US group exhibited markedly higher mRNA levels of TNF-α and IFN-γ compared with the NKP-1339-NBs+US and other treatment groups (<em>P</em> &lt; 0.05, Fig. <a href="#F5" class="usa-link">5</a>L and M).</p>
<p>The above results indicate that NKP-1339/miR-142-NBs combined with US treatment can considerably promote CD8<sup>+</sup> T cell proliferation and cytotoxicity, enhance the secretion of immune-related molecules such as TNF-α and IFN-γ, and further strengthen the tumor immune response. This antitumor immune activity may be achieved through the blockade of the programmed death-1 (PD-1)/PD-L1 pathway, enhancing the function of CTLs. These findings provide strong evidence for the application of targeted nanobubble-based drug delivery systems in tumor immunotherapy.</p></section></section><section id="sec29"><h3 class="pmc_sec_title">NKP-1339/miR-142-NBs+US induced ICD mediated by mitochondrial dysfunction</h3>
<section id="sec30"><h4 class="pmc_sec_title">NKP-1339/miR-142-NBs+US induced ICD</h4>
<p>CRT externalization is a key marker of ICD, and its exposure can trigger the phagocytosis of apoptotic tumor cells by macrophages in the TME, thereby activating an immune response. To explore the potential of NKP-1339/miR-142-NBs combined with US treatment to induce ICD, the expression and externalization of CRT were assessed using immunofluorescence, flow cytometry, and WB. As shown in Fig. <a href="#F6" class="usa-link">6</a>A and C, all treatment groups (NKP-1339, NKP-1339+US, NKP-1339-NBs+US, and NKP-1339/miR-142-NBs+US) considerablypromoted the externalization of CRT onto tumor cell membranes, with the strongest green fluorescence signal observed in the NKP-1339/miR-142-NBs+US group, indicating the highest level of CRT externalization. Flow cytometric analysis revealed that CRT externalization in the NKP-1339/miR-142-NBs+US group reached its highest level of 53.39% (<em>P</em> &lt; 0.01, Fig. <a href="#F6" class="usa-link">6</a>B and D), which was markedly higher than that in the other groups. WB further confirmed that CRT protein expression was enhanced in the combined treatment group (<em>P</em> &lt; 0.05, Fig. <a href="#F6" class="usa-link">6</a>E and F).</p>
<figure class="fig xbox font-sm" id="F6"><h5 class="obj_head">Fig. 6.</h5>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><img class="graphic" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3dd3/12334082/c2921b9eafbc/bmr.0232.fig.006.jpg" loading="lazy" height="660" width="498" alt="Fig. 6."></p>
<div class="p text-right font-secondary"><a href="figure/F6/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Mechanism on augmented ICD induced by NKP-1339/miR-142-NBs combined with US treatment. (A and C) Immunofluorescence analysis of CRT exposure on the surface of tumor cells in different treatment groups and semiquantitative analysis (200×, scale bar = 100 μm). (B and D) Flow cytometry analysis of CRT expression levels in each group and quantitative analysis. (E to I) Western blot analysis of CRT, HMGB1, HSP70, and HSP90 release levels and semiquantitative analysis. (J) qPCR analysis of mRNA expression levels of CRT, HMGB1, HSP70, and HSP90. *<em>P</em> &lt; 0.05, **<em>P</em> &lt; 0.01, ***<em>P</em> &lt; 0.001.</p></figcaption></figure><p>HMGB1 release is another important feature of ICD that further enhances antitumor immunity by activating dendritic and T cells in the immune system. As shown in Fig. <a href="#F6" class="usa-link">6</a>E, WB analysis indicated that, compared with the control group, NKP-1339 induced the expression of HMGB1. The HMGB1 expression level in the NKP-1339-NBs+US group was further elevated compared to that in the NKP-1339 and NKP-1339+US groups (<em>P</em> &lt; 0.05, Fig. <a href="#F6" class="usa-link">6</a>E and G). Notably, the NKP-1339/miR-142-NBs+US group exhibited the highest expression of HMGB1, considerably higher than that in the miR-142-5p, miR-142-NBs+US, and NKP-1339-NBs+US groups (<em>P</em> &lt; 0.05), indicating that the combined treatment markedly enhanced the ICD response.</p>
<p>HSP70 and HSP90 are critical indicators of cellular stress responses and play key roles in ICD. The externalization of HSP70 on the cell surface enhances immune cell recognition and activates antitumor immune responses, while the release of HSP90 participates in regulating the DAMPs’ signaling pathway. WB results showed that compared with that in the control group, HSP70 expression was increased in the NKP-1339 group and was further enhanced in the NKP-1339+US group (<em>P</em> &lt; 0.05). The expression of HSP70 was even higher in the NKP-1339-NBs+US group (Fig. <a href="#F6" class="usa-link">6</a>E and H). Most importantly, HSP70 expression peaked in the NKP-1339/miR-142-NBs+US group and was higher than that in the miR-142-5p, miR-142-NBs+US, and NKP-1339-NBs+US groups (<em>P</em> &lt; 0.05, Fig. <a href="#F6" class="usa-link">6</a>H), further confirming the immunogenicity of the combined treatment. The expression pattern of HSP90 was consistent with that of HSP70 (Fig. <a href="#F6" class="usa-link">6</a>I). The qPCR results for CRT, HMGB1, HSP70, and HSP90 showed trends similar to those observed using WB (Fig. <a href="#F6" class="usa-link">6</a>J), further validating the ICD effect of the combined treatment.</p>
<p>These results indicate that NKP-1339/miR-142-NBs combined with US treatment can effectively induce ICD in tumor cells, mainly through CRT externalization, HMGB1 release, and the up-regulation of HSP70 and HSP90, thereby further activating antitumor immune responses. The combined treatment group showed significant improvements in all ICD markers.</p></section><section id="sec31"><h4 class="pmc_sec_title">NKP-1339/miR-142-NBs+US enhanced DC cell maturation</h4>
<p>An increasing body of research suggests that the activation of ICD facilitates the exposure of tumor-associated antigens and stimulates DC activation, leading to tumor-specific T cell infiltration through a dramatic surge in DAMPs. To evaluate T cell-mediated immune responses, immunofluorescence staining was used to assess the infiltration of CD80<sup>+</sup> CD86<sup>+</sup> cells into tumor tissues. As depicted in Fig. <a href="#supplementary-material-1" class="usa-link">S3</a>A and B, and D and E, the NKP-1339 group exhibited a higher number of CD80<sup>+</sup> CD86<sup>+</sup> cells than the control group (<em>P</em> &lt; 0.001, Fig. <a href="#supplementary-material-1" class="usa-link">S3</a>D and E). Additionally, the NKP-1339-NBs+US group demonstrated notably enhanced expression of CD80<sup>+</sup> CD86<sup>+</sup> proteins compared with the N-NBs+US and NKP-1339+US groups (<em>P</em> &lt; 0.05, Fig. <a href="#supplementary-material-1" class="usa-link">S3</a>D and E). The NKP-1339/miR-142-NBs+US group showed the highest levels of CD80<sup>+</sup>CD86<sup>+</sup> expression, which were higher than those observed in the other treatment groups (<em>P</em> &lt; 0.05, Fig. <a href="#supplementary-material-1" class="usa-link">S3</a>D and E), indicating that the combined treatment more effectively promoted DC maturation.</p>
<p>NK cell activation plays a pivotal role in the antitumor immune response induced by ICD. Flow cytometric analysis of mouse spleen cells revealed a higher proportion of NK cells in the NKP-1339+US group than in the control group, with the NKP-1339-NBs+US group showing a further increase in the NK cell proportion (<em>P</em> &lt; 0.05). The NKP-1339/miR-142-NBs+US group showed the highest proportion of NK cells (<em>P</em> &lt; 0.05, Fig. <a href="#supplementary-material-1" class="usa-link">S3</a>C and F). Additionally, NK cell cytotoxicity against tumor cells, as assessed using an LDH release assay, followed the same trend as NK cell proportions, with the NKP-1339/miR-142-NBs+US group exhibiting the most significant cytotoxicity (<em>P</em> &lt; 0.05, Fig. <a href="#supplementary-material-1" class="usa-link">S3</a>G).</p></section><section id="sec32"><h4 class="pmc_sec_title">NKP-1339/miR-142-NBs+US induced ICD mediated by mitochondrial structural and functional disruptions</h4>
<section id="sec33"><h5 class="pmc_sec_title">NKP-1339/miR-142-NBs+US induced mitochondrial oxidative stress and dysfunction</h5>
<p>ATP production is a central function of mitochondria and serves as the basis for all cellular physiological activities. ATP generation relies on the mitochondrial electron transport chain, and its efficiency not only directly affects the cellular energy supply but also closely correlates with the production of ROS and calcium homeostasis. When ATP production decreases, the efficiency of the electron transport chain decreases, leading to increased electron leakage, which subsequently elevates ROS levels and disrupts calcium homeostasis. In changes to mitochondrial ATP levels, normal conditions maintain high ATP production to meet energy demands, whereas under damage conditions, ATP generation declines and leakage increases. During immune activation, ATP leakage can serve as an immune signal, enhancing the antitumor effects. Analysis of mitochondrial ATP levels revealed that ATP generation in the control and N-NBs+US groups was relatively high. However, in the NKP-1339 group, ATP levels were considerably reduced, indicating mitochondrial damage, with further decreases observed in the NKP-1339+US group. The ATP content in the NKP-1339-NBs+US group was lower (<em>P</em> &lt; 0.05, Fig. <a href="#F7" class="usa-link">7</a>C), and the ATP levels in the NKP-1339/miR-142-NBs+US group were the lowest (<em>P</em> &lt; 0.05), suggesting that the combined treatment exacerbates mitochondrial damage.</p>
<figure class="fig xbox font-sm" id="F7"><h6 class="obj_head">Fig. 7.</h6>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><img class="graphic" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3dd3/12334082/71826b30d48c/bmr.0232.fig.007.jpg" loading="lazy" height="660" width="486" alt="Fig. 7."></p>
<div class="p text-right font-secondary"><a href="figure/F7/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>NKP-1339/miR-142-NBs combined with US treatment synergistically disrupt mitochondrial function via concurrent ATP depletion, ROS burst, and calcium dysregulation. (A and D) Immunofluorescence staining to detect ROS levels within esophageal cancer cells and semiquantitative analysis (200×, scale bar = 100μm). (B and F) Flow cytometry-based quantification of ROS-positive cell percentage. (C) Mitochondrial ATP levels measurement. (E to G) Flow cytometry analysis of calcium ion concentration changes and quantitative analysis. *<em>P</em> &lt; 0.05, **<em>P</em> &lt; 0.01, ***<em>P</em> &lt; 0.001.</p></figcaption></figure><p>ROS and Ca<sup>2+</sup> are key regulators of mitochondrial function, influencing mitochondrial status through oxidative stress and calcium homeostasis, and also play important roles in regulating mitochondrial fission and fusion [<a href="#B18" class="usa-link" aria-describedby="B18">18</a>]. Mitochondria are the primary sources of ROS, which are by-products of ATP production. When present in appropriate amounts, ROS participate in signaling, but excess ROS induces oxidative damage. Excessive ROS can lead to calcium overload, triggering mitochondrial permeability transition (MPT) and ROS release, creating a vicious cycle [<a href="#B19" class="usa-link" aria-describedby="B19">19</a>]. Mitochondrial damage is often accompanied by excessive ROS production, leading to mitochondrial dysfunction and cellular stress. Intracellular ROS levels were examined using immunofluorescence staining. The results showed that ROS generation in the NKP-1339 group was increased compared with that in the control group and was further elevated in the NKP-1339+US and NKP-1339-NBs+US groups. Notably, the NKP-1339/miR-142-NBs+US group exhibited the highest ROS fluorescence intensity, which was higher than that of all other groups (<em>P</em> &lt; 0.05, Fig. <a href="#F7" class="usa-link">7</a>A and D), indicating that the combination of the drug and gene-loaded NBs under US exposure considerably induced oxidative stress in tumor cells. Subsequently, flow cytometry was used to quantify the cellular ROS levels, and the results were consistent with the immunofluorescence trends. Compared to the control and empty NBs groups, the NKP-1339 group showed a significant increase in the proportion of ROS-positive cells, with the NKP-1339-NBs+US group showing further elevation compared to the N-NBs+US and NKP-1339+US groups (<em>P</em> &lt; 0.05). The highest proportion of ROS-positive cells (60.17 %) was observed in the NKP-1339/miR-142-NBs+US group, indicating a strong oxidative stress response (<em>P</em> &lt; 0.05, Fig. <a href="#F7" class="usa-link">7</a>B and F).</p>
<p>Mitochondria maintain homeostasis by regulating calcium ion flux, and calcium signaling plays a critical role in the regulation of ATP and ROS production. ROS enhances the activity of calcium channels, thereby establishing a positive feedback loop between ROS and calcium ions [<a href="#B20" class="usa-link" aria-describedby="B20">20</a>]. Calcium overload can lead to ROS accumulation and trigger MPT, halting ATP production [<a href="#B21" class="usa-link" aria-describedby="B21">21</a>]. This process further promotes mitochondrial division through the interaction between Drp1 and Fis1, exacerbating mitochondrial dysfunction and activating cell death signaling [<a href="#B22" class="usa-link" aria-describedby="B22">22</a>]. To investigate the calcium ion release under different treatment conditions, we analyzed the changes in calcium concentration in esophageal cancer cells using flow cytometry (Fig. <a href="#F7" class="usa-link">7</a>E). The results demonstrated that calcium levels in the control group were maintained at low levels. In contrast, the NKP-1339 and NKP-1339+US groups exhibited a significant increase in the percentage of calcium-positive cells, suggesting that US facilitated mitochondrial calcium release and disrupted mitochondrial calcium homeostasis. In the combination treatment groups, the NKP-1339-NBs+US group showed a further increase in mitochondrial calcium levels compared to the NKP-1339+US group (<em>P</em> &lt; 0.001, Fig. <a href="#F7" class="usa-link">7</a>E and G), indicating that the synergistic effect of NBs and US exacerbated calcium release. The most significant change occurred in the NKP-1339/miR-142-NBs+US group, which had the highest percentage of calcium-positive cells (<em>P</em> &lt; 0.001, Fig. <a href="#F7" class="usa-link">7</a>G). These findings suggest that drug and gene combination therapy under US exposure may promote the opening of mitochondrial permeability transition pores (mPTPs), leading to a massive release of mitochondrial calcium stores into the cytoplasm, thus accelerating mitochondrial dysfunction.</p>
<p>This study demonstrates that the NKP-1339/miR-142-NBs combined with US treatment induced a decrease in mitochondrial ATP levels, markedly increased mitochondrial ROS levels, and promoted opening of the mPTP. The massive release of mitochondrial calcium stores into the cytoplasm disrupts calcium homeostasis, thereby forming a vicious cycle that accelerates mitochondrial damage. These results suggest that NKP-1339/miR-142-NBs-mediated mitochondrial dysfunction is closely associated with ROS generation and mPTP opening.</p></section><section id="sec34"><h5 class="pmc_sec_title">NKP-1339/miR-142-NBs+US induced mitochondrial fission disorder</h5>
<p>Mitochondrial fission and fusion maintain morphology, function, and cellular homeostasis through dynamic balance. Fission isolates damaged mitochondria, while fusion optimizes the network to support ATP production and ROS clearance. These processes are regulated by ROS [<a href="#B23" class="usa-link" aria-describedby="B23">23</a>], calcium [<a href="#B24" class="usa-link" aria-describedby="B24">24</a>], and ATP [<a href="#B25" class="usa-link" aria-describedby="B25">25</a>] to ensure cellular homeostasis. Under normal conditions, DRP1 and FIS1 are key regulatory proteins for mitochondrial fission; DRP1 executes the fission process, and FIS1 acts as its outer membrane receptor. OPA1 and MFN2 regulate the fusion of inner and outer mitochondrial membranes, respectively, while maintaining mitochondrial network integrity. PGC1-α is a key regulator of mitochondrial biogenesis, promoting mitochondrial genesis, mitochondrial DNA (mtDNA) transcription, and replication by activating downstream proteins such as NRF1 and TFAM. The up-regulation of DRP1 and FIS1 typically indicates enhanced fission, whereas the down-regulation of OPA1 and MFN2 indicates impaired fusion. The activity of PGC1-α, NRF1, and TFAM is closely related to mitochondrial biogenesis and functional recovery, collectively regulating mitochondrial morphology, function, and homeostasis. In states of mitochondrial damage, fission is enhanced while fusion is suppressed, leading to mitochondrial fragmentation, increased ROS production, mtDNA release, and dysfunction. Mitochondrial dynamics are closely linked to immune activation, with activated immune cells exhibiting high fission rates. Mitochondrial fission has been shown to enhance the activation of the NLRP3 inflammasome and release pro-inflammatory cytokines [<a href="#B26" class="usa-link" aria-describedby="B26">26</a>], whereas the leakage of mtDNA can activate immune responses via the cyclic GMP-AMP synthase–stimulator of interferon genes pathway [<a href="#B27" class="usa-link" aria-describedby="B27">27</a>].</p>
<p>To further “visualize” mitochondrial damage, the mitochondria-specific fluorescence probe MitoTracker was used to observe morphological changes under different treatment conditions. Fluorescence confocal microscopy showed that in the control and N-NBs+US groups, mitochondria exhibited typical linear and network structures with intact, continuous morphology, clear cristae, and minimal fission. In the NKP-1339 group, mitochondria showed mild fragmentation with localized breakage and a shrinking morphology. With the addition of US-assisted treatment (NKP-1339+US group), mitochondrial damage worsened, and some mitochondrial structures showed fragmentation. In the NKP-1339-NBs+US group, the mitochondria shifted considerably to a fragmented state, displaying more broken and dot-like structures. The most severe mitochondrial damage was observed in the NKP-1339/miR-142-NBs+US group, where mitochondria showed extensive fragmentation, lost the network structure entirely, and exhibited only dot-like and broken shapes (Fig. <a href="#F8" class="usa-link">8</a>A and D).</p>
<figure class="fig xbox font-sm" id="F8"><h6 class="obj_head">Fig. 8.</h6>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><img class="graphic" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3dd3/12334082/3dfda0ed7777/bmr.0232.fig.008.jpg" loading="lazy" height="660" width="521" alt="Fig. 8."></p>
<div class="p text-right font-secondary"><a href="figure/F8/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>NKP-1339/miR-142-NBs combined with US treatment provoke pathological mitochondrial fission leading to structural disintegration in esophageal cancer cells. (A and D) Confocal fluorescence microscopy images of esophageal cancer cells showing mitochondrial fluorescence, with quantification of fragmented cells (scale bar = 50 μm). (C) Diagram of mitochondrial fission-regulating genes. (B and E) Representative TEM images (×20,000) of mitochondria in esophageal tumor tissues from different groups, and quantification of damaged mitochondria. Scale bar = 500 nm. (F to I) WB analysis of mitochondrial fission and fusion-related proteins, with semiquantitative analysis. (J to P) qPCR analysis of mRNA expression levels of mitochondrial function-related genes (DRP1, FIS1, OPA1, PGC1-α, NRF1, MFN2, and TFAM). *<em>P</em> &lt; 0.05, **<em>P</em> &lt; 0.01, ***<em>P</em> &lt; 0.001.</p></figcaption></figure><p>To further assess mitochondrial ultrastructure, transmission electron microscopy was conducted on each group. In the Control and N-NBs+US groups, mitochondria maintained an intact architecture, characterized by well-preserved cristae and continuous double membranes. In contrast, the NKP-1339 group exhibited mild mitochondrial swelling and partial cristae disorganization. More pronounced structural damage was observed in the NKP-1339+US and NKP-1339-NBs+US groups, including disrupted membranes and widespread cristae loss. Notably, the NKP-1339/miR-142-NBs+US group displayed extensive mitochondrial injury, as evidenced by pronounced swelling, collapsed cristae, and rupture of the outer membrane—hallmarks indicative of severe mitochondrial destruction (Fig. <a href="#F8" class="usa-link">8</a>B and E). Quantitative analysis further demonstrated a markedly increased proportion of damaged mitochondria in the codelivery+US group compared to all other groups (Fig. <a href="#F8" class="usa-link">8</a>B and E).</p>
<p>WB analysis revealed that the mitochondrial fission-related protein DRP1 was markedly up-regulated in the NKP-1339 group, while the expression of fusion and biogenesis-related proteins OPA1 and PGC1-α was down-regulated. This trend was further exacerbated in the NKP-1339+US group, with DRP1 showing a more significant up-regulation (<em>P</em> &lt; 0.01), and OPA1 and PGC1-α showing significant down-regulation (<em>P</em> &lt; 0.05). In the NKP-1339-NBs+US group, DRP1 expression was the highest, and OPA1 and PGC1-α expression were the lowest (<em>P</em> &lt; 0.05) (Fig. <a href="#F8" class="usa-link">8</a>F to I).</p>
<p>Further qPCR analysis of mitochondrial function-related genes, including DRP1, FIS1, OPA1, PGC1-α, NRF1, MFN2, and TFAM, revealed that DRP1 and FIS1 were considerably up-regulated in all treatment groups (<em>P</em> &lt; 0.05), while OPA1, PGC1-α, NRF1, MFN2, and TFAM levels gradually decreased, with the most significant changes observed in the NKP-1339/miR-142-NBs+US group compared to the miR-142-5p, miR-142-NBs+US, and NKP-1339-NBs+US groups (<em>P</em> &lt; 0.05) (Fig. <a href="#F8" class="usa-link">8</a>J to P). These results were consistent with the WB data, indicating that the combination treatment notably exacerbated mitochondrial dysfunction by promoting mitochondrial fission and inhibiting fusion and biogenesis.</p>
<p>In conclusion, the NKP-1339/miR-142-NBs combined with US treatment induced significant mitochondrial structural damage, up-regulated fission proteins (DRP1 and FIS1), and down-regulated fusion and biogenesis-related genes (OPA1, PGC1-α, NRF1, MFN2, and TFAM), suggesting that mitochondrial dysfunction may be linked to tumor cell apoptosis and ICD responses.</p></section><section id="sec35"><h5 class="pmc_sec_title">Mitochondrial fission disruption mediates ICD</h5>
<p>To further investigate the role of mitochondrial fission in NKP-1339-induced ICD, tumor cells were treated with a mitochondrial fission inhibitor. The experimental groups included control, Mdivi-1 (mitochondrial fission inhibitor treatment), NKP-1339, and NKP-1339+Mdivi-1 groups. The expression of ICD-related markers, including CRT, HMGB1, HSP70, and HSP90, was measured using WB, qPCR, and flow cytometry (Fig. <a href="#F9" class="usa-link">9</a>A to I). Both WB and qPCR results indicated no significant differences in the expression of CRT, HMGB1, HSP70, and HSP90 between the Mdivi-1-treated and control groups (<em>P</em> &gt; 0.05), suggesting that the mitochondrial fission inhibitor alone had limited effects on ICD markers. The NKP-1339 treatment group showed notably up-regulated expression of CRT, HMGB1, HSP70, and HSP90 (<em>P</em> &lt; 0.01), indicating that NKP-1339 effectively induced ICD. However, in the NKP-1339+Mdivi-1 combination treatment group, the expression of these ICD markers was considerably lower than that in the NKP-1339-only treatment group (<em>P</em> &lt; 0.05), suggesting that the mitochondrial fission inhibitor partially reversed the ICD-inducing effect of NKP-1339. Flow cytometry analysis of CRT exposure further confirmed that CRT externalization levels did not differ between the Mdivi-1 and control groups (<em>P</em> &gt; 0.05), whereas CRT exposure was increased in the NKP-1339-treated group (<em>P</em> &lt; 0.001) and decreased in the NKP-1339+Mdivi-1 group (<em>P</em> &lt; 0.05, Fig. <a href="#F9" class="usa-link">9</a>J and K).</p>
<figure class="fig xbox font-sm" id="F9"><h6 class="obj_head">Fig. 9.</h6>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><img class="graphic" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3dd3/12334082/b9d691c00890/bmr.0232.fig.009.jpg" loading="lazy" height="660" width="514" alt="Fig. 9."></p>
<div class="p text-right font-secondary"><a href="figure/F9/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>From mitochondrial fission suppression to enhanced ICD: The regulatory axis of NKP-1339 and fission inhibitors in tumor immunogenicity. (A to E) WB analysis of CRT, HMGB1, HSP70, and HSP90 protein expression levels, along with semiquantitative analysis. (F to I) qPCR analysis of CRT, HMGB1, HSP70, and HSP90 mRNA expression levels. (J and K) Flow cytometry analysis of CRT expression levels and quantitative analysis. (L to N) Representative immunofluorescence images showing Drp1 (red), calreticulin (CRT, green), and nuclei (blue) in different treatment groups. White arrows indicate representative tumor cells with synchronous activation , along with semiquantitative analysis. Scale bar = 20 μm. *<em>P</em> &lt; 0.05, **<em>P</em> &lt; 0.01, ***<em>P</em> &lt; 0.001.</p></figcaption></figure><p>To further elucidate the spatial correlation between mitochondrial fission and ICD, dual immunofluorescence staining for Drp1 (red) and CRT (green) was performed on tumor tissue sections. In the Control and Mdivi-1 groups, CRT expression was restricted to intracellular compartments without detectable membrane localization. In contrast, NKP-1339 treatment markedly increased cytoplasmic Drp1 puncta, indicating activated mitochondrial fission, and simultaneously promoted CRT externalization, forming a distinct green fluorescent ring along the plasma membrane (Fig. <a href="#F9" class="usa-link">9</a>L to N). Although no colocalization was observed due to their distinct subcellular localizations, the 2 signals were consistently elevated within the same cells. Notably, in the NKP-1339+Mdivi-1 group, both Drp1 clustering and CRT membrane exposure were substantially reduced, suggesting that mitochondrial fission plays a functional role in promoting CRT translocation and ICD initiation. These results underscore the critical involvement of Drp1 in mediating NKP-1339-induced ICD responses.</p>
<p>These results suggest that NKP-1339 induces ICD by up-regulating ICD markers and that the inclusion of the mitochondrial fission inhibitor partially attenuates this effect, indicating a close relationship between NKP-1339-induced ICD and mitochondrial fission.</p></section></section></section><section id="sec36"><h3 class="pmc_sec_title">Safety assessment of NKP-1339/miR-142-NBs</h3>
<p>To evaluate the in vivo safety of NKP-1339/miR-142-NBs, H&amp;E staining was used to examine histopathological changes in the major organs (heart, liver, spleen, lungs, and kidney) of mice in each group. The experimental results indicated that the organ structures of mice in all groups remained intact, with no significant signs of inflammation, necrosis, or other pathological damage. Tissue morphology was normal (Fig. <a href="#supplementary-material-1" class="usa-link">S4</a>A). Further measurements of the liver and kidney indices showed no statistically significant differences between the treatment and control groups (Fig. <a href="#supplementary-material-1" class="usa-link">S4</a>B and C). These data suggest that NKP-1339/miR-142-NBs did not affect the liver or kidney function during treatment.</p>
<p>In conclusion, NKP-1339/miR-142-NBs exhibited good biocompatibility and safety in tumor-bearing mice, with no significant pathological changes or toxic side effects, demonstrating a high level of safety and promising therapeutic potential.</p></section></section><section id="sec37"><h2 class="pmc_sec_title">Discussion</h2>
<p>US NBs are novel drug-delivery platforms with significant advantages in cancer therapy owing to their targeting ability and multifunctionality. With a nanoscale diameter (&lt;500 nm), NBs accumulate at tumor sites via EPR effects, penetrate abnormal vascular barriers, and promote drug enrichment in the TME [<a href="#B28" class="usa-link" aria-describedby="B28">28</a>]. The positively charged surface of NBs interacts with the negatively charged TME, enhancing the targeted delivery efficiency [<a href="#B29" class="usa-link" aria-describedby="B29">29</a>]. Compared to traditional viral vectors, NBs are an ideal choice for delivering genes, chemotherapeutic agents, and immunotherapy molecules because of their low immunogenicity, ease of preparation, and good safety profile. The cationic lipid shell of NBs improves the drug-loading capacity and stability of miRNAs, preventing their rapid degradation in vivo [<a href="#B30" class="usa-link" aria-describedby="B30">30</a>]. Upon US activation, NBs utilize cavitation and sonoporation effects to enhance cell membrane permeability [<a href="#B31" class="usa-link" aria-describedby="B31">31</a>], improve tumor cell uptake of NKP-1339 and miR-142-5p, enable spatiotemporally controlled drug release, and minimize off-target toxicity to healthy tissues. Our team discovered that NBs effectively delivered Ce6 and miR-195, leading to successful cervical cancer treatment. In this study, we developed a multifunctional nanolipobubble system loaded with NKP-1339 and miR-142 for efficient delivery and precise release via US targeting. Pharmacokinetic studies showed that NKP-1339/miR-142-NBs US prolongs drug circulation, enhances accumulation in tumor tissues, and reduces nonspecific distribution in healthy tissues. This system improved NKP-1339 stability and reduced its systemic toxicity, offering an effective strategy for precise anticancer therapy.</p>
<p>ICD has gained attention as a combination cancer therapy that complements traditional treatments and immunotherapies. Studies have shown that various ICD inducers, such as chemotherapeutic agents, photosensitizers, and radiation, activate antitumor immune responses by inducing cellular stress, and stimulating the release of DAMPs, which inhibit cancer progression [<a href="#B32" class="usa-link" aria-describedby="B32">32</a>]. Increasing evidence suggests that mitochondria play a critical role in immune modulation [<a href="#B33" class="usa-link" aria-describedby="B33">33</a>]. Because of the lack of histone protective packaging, mtDNA is particularly vulnerable to stress-induced damage. Mitochondrial dysfunction, such as ROS generation, ATP leakage, and cytochrome c release, is associated with ICD activation [<a href="#B34" class="usa-link" aria-describedby="B34">34</a>]. Induction of mitochondrial stress exposes immunogenic mitochondrial antigens and regulates antitumor immune responses [<a href="#B35" class="usa-link" aria-describedby="B35">35</a>]. Moreover, mitochondrial stress amplifies stress signals by coupling with the ER, thereby enhancing antitumor immunity. Mitochondria are ideal targets for ICD inducers and provide insights into mitochondrial stress during ICD induction. Mitochondria are central regulators of cellular energy and are linked to cancer cell survival. Both exogenous and endogenous stressors damage the mitochondria, leading to excessive ROS production and oxidative stress. Oxidative stress impairs mitochondrial function, reduces ATP generation, triggers apoptosis, and releases DAMPs, further promoting ICD. ER and mitochondria maintain calcium homeostasis. Disruption of calcium homeostasis, particularly mitochondrial calcium overload, induces mitochondrial dysfunction, cell death, and ICD [<a href="#B36" class="usa-link" aria-describedby="B36">36</a>]. Furthermore, ROS imbalance disrupts mitochondrial dynamics, altering the expression of genes related to fission and biogenesis (e.g., DRP1, OPA1, and PGC1-α), further compromising mitochondrial function [<a href="#B37" class="usa-link" aria-describedby="B37">37</a>]. NKP-1339, a novel ICD inducer, exerts antitumor effects by depleting mitochondrial ATP, promoting ROS generation, disrupting mitochondrial calcium homeostasis, triggering mitochondrial dysfunction, and amplifying ICD effects. Additionally, DAMPs released by NKP-1339 enhanced antigen-presenting cell activity and activated DC maturation, further amplifying the immune response. These findings highlight the unique advantages of NKP-1339 in inducing ICD and enhancing antitumor immunity, thus supporting the development of NKP-1339-based ICD therapies.</p>
<p>Immune checkpoint inhibitor (ICI) therapy, which restores T cell activity by blocking the PD-1/PD-L1 pathway, is an important strategy in cancer immunotherapy to induce antitumor immune responses. However, the efficacy of single-agent ICI therapy is limited by poor immunogenicity, particularly in “cold tumors” with minimal immune infiltration. Therefore, combining ICI therapy with other treatments is necessary to convert “cold tumors” into “hot tumors” and enhance immune responses. For example, combining ICI with chemotherapy [<a href="#B38" class="usa-link" aria-describedby="B38">38</a>], radiotherapy, or targeted therapy [<a href="#B39" class="usa-link" aria-describedby="B39">39</a>] can improve the effectiveness of immunotherapy by enhancing antigen presentation, activating T cells, and reducing the number of immunosuppressive cells. miR-142, a key tumor-suppressive miRNA, regulates cell proliferation, invasion, and apoptosis and enhances T cell activity by down-regulating PD-L1 expression, thereby improving ICI efficacy. Studies have indicated that miR-142-5p alleviates the immunosuppressive TME by inhibiting PD-L1 expression. PD-L1 not only is highly expressed in various tumor cells but also plays a crucial immunosuppressive role in certain normal immune cells, such as activated T cells, B cells, and DCs, where it contributes to maintaining peripheral immune tolerance. Previous studies have demonstrated that PD-L1-deficient mice exhibit heightened T cell reactivity and increased susceptibility to autoimmune diseases in preclinical models [<a href="#B40" class="usa-link" aria-describedby="B40">40</a>]. Therefore, in theory, systemic delivery of miR-142-5p may lead to unintended down-regulation of PD-L1 in normal immune cells, potentially disrupting immune homeostasis and triggering immune overactivation or autoimmunity-related toxicity. However, to date, there is no direct clinical or preclinical evidence linking systemic miR-142-5p therapy to the onset of autoimmune diseases. Moreover, several miRNAs, including miR-142-5p, miR-155, and miR-200c, have been reported to down-regulate PD-L1 expression and enhance antitumor immunity [<a href="#B41" class="usa-link" aria-describedby="B41">41</a>,<a href="#B42" class="usa-link" aria-describedby="B42">42</a>]. In our study, we employed an ultrasound-responsive NB-based delivery system, which offers excellent tumor-targeting capability and spatiotemporally controlled release. This strategy reduces the nonspecific distribution of miRNAs in normal tissues [<a href="#B43" class="usa-link" aria-describedby="B43">43</a>]. Pharmacokinetic and biodistribution analyses further demonstrated that NKP-1339/miR-142-5p-NBs exhibited prolonged tumor retention and high intratumoral accumulation, while showing minimal distribution in major immune organs such as the spleen. These findings suggest that the systemic exposure of miR-142-5p is limited when delivered via NBs, thereby minimizing the risk of off-target effects in normal immune cells. Additionally, histopathological evaluations of major organs and serum biochemical analyses of liver and kidney function revealed no significant pathological alterations or systemic toxicity.</p>
<p>The combined application of chemotherapy and gene therapy has become a major focus in cancer treatment, as both strategies complement each other through different mechanisms and offer novel therapeutic options for refractory cancers [<a href="#B44" class="usa-link" aria-describedby="B44">44</a>]. Gene therapy achieves precise treatment by modulating oncogenes or restoring tumor suppressor genes [<a href="#B45" class="usa-link" aria-describedby="B45">45</a>], whereas chemotherapy combined with immunotherapy uses chemotherapeutic agents to kill cancer cells and immunotherapy to enhance immune system function. Some chemotherapy drugs induce ICD, making cancer cells more susceptible to immune recognition, whereas immune therapy boosts the immune response, kills cancer cells, and enhances immunity [<a href="#B46" class="usa-link" aria-describedby="B46">46</a>]. The combination of chemotherapy, immunotherapy, and gene therapy may be more effective than monotherapy by providing targeted destruction, reducing side effects, and improving the quality of life, while overcoming drug resistance and promoting durable responses [<a href="#B44" class="usa-link" aria-describedby="B44">44</a>]. In this study, the combination of NKP-1339 and miR-142-5P represents a typical example of complementary gene therapy and immunotherapy for combating the high invasiveness and resistance of esophageal cancer. NKP-1339 promotes antigen presentation by inducing mitochondrial dysfunction and releasing immunogenic death signals, whereas miR-142-5P enhances T cell activity by down-regulating PD-L1 expression, resulting in T cell proliferation and antitumor cytotoxicity through MHC-TCR activation. This synergy between chemotherapy, immunotherapy, and gene therapy demonstrates strong mechanistic complementarity and enhances antitumor efficacy.</p>
<p>ICD can effectively trigger tumor antigen release and initiate antitumor immune responses; however, studies have shown that without sufficient induction of memory T cells, the resulting immune activation may be transient and inadequate to prevent tumor recurrence [<a href="#B47" class="usa-link" aria-describedby="B47">47</a>]. Similarly, miRNA-mediated PD-L1 inhibition can effectively relieve immunosuppression and enhance T cell activation and cytokine production in the short term [<a href="#B48" class="usa-link" aria-describedby="B48">48</a>], but such strategies alone may fail to sustain robust immune responses in the absence of long-lived memory T cells [<a href="#B49" class="usa-link" aria-describedby="B49">49</a>]. These findings suggest that ICD-based therapies alone are insufficient for long-term tumor eradication, and additional strategies that promote immune memory formation are required. Recently, the phase Ib study by the Spanish Sarcoma Group (GEIS) demonstrates that the combination of doxorubicin, dacarbazine, and nivolumab is a tolerable and potentially effective first-line therapy for advanced leiomyosarcoma, showing a 34.4% objective response rate and a median progression-free survival of 7.2 months. The combination leverages ICD induced by doxorubicin (HMGB1/ATP release) and synergizing with nivolumab’s PD-1 blockade to enhance T cell activation and overcome tumor immune evasion in advanced leiomyosarcoma, indicating that ICD–ICI synergy may enhance T cell activation and reduce immune escape [<a href="#B50" class="usa-link" aria-describedby="B50">50</a>]. From a translational perspective, although this strategy exhibits a favorable safety profile and strong immunostimulatory activity in animal models, several critical challenges must be addressed before clinical application. Scalable and reproducible manufacturing of nanobubbles with consistent drug loading efficiency, size distribution, and ultrasound responsiveness is essential for industrialization. Moreover, the potential off-target effects of miR-142-5p—especially its impact on PD-L1 expression in normal immune cells—must be rigorously evaluated to mitigate risks of immune dysregulation or autoimmune toxicity. Additionally, human tumors exhibit substantial immunological heterogeneity, and further validation in patient-derived organoids or humanized mouse models is needed. These considerations are critical for future preclinical and clinical development.</p>
<p>In conclusion, this study introduced a combination of NKP-1339 and miR-142-5P using US-targeted NBs for esophageal cancer therapy, showing significant antitumor effects. Compared with individual treatments, combined therapy considerably enhanced efficacy. This was achieved through US NBs, which enhance drug penetration and local concentration in tumor tissues via the cavitation effect. Additionally, this combination triggers mitochondrial damage and dysfunction, inducing ICD, which promotes tumor-associated antigen release and activates the immune response. At the molecular level, NKP-1339/miR-142-5P-NBs reduce mitochondrial ATP production, increase ROS levels, and disrupt calcium homeostasis, resulting in mitochondrial damage. This damage disrupts mitochondrial dynamics, up-regulates the expression of ICD-related molecules, such as CRT and HMGB1, activates ICD signaling pathways, and enhances antitumor immune responses. Combined therapy also enhances NK cell function. miR-142, by down-regulating PD-L1 expression and blocking the PD-1/PD-L1 pathway, alleviates tumor-induced immune suppression, promoting CD3<sup>+</sup> CD8<sup>+</sup> T cell proliferation and restoring T cell activity via increased interferon-γ expression. Thus, NKP-1339 and miR-142 NBs combined US therapy induced mitochondrial dysfunction and ICD, enhanced CTL activity, and synergistically triggered immune responses. This study uncovers a new mechanism for combining chemotherapy–immunotherapy with gene-targeted therapy, demonstrating promising biological safety and therapeutic potential for esophageal cancer treatment.</p></section><section id="ack1" class="ack"><h2 class="pmc_sec_title">Acknowledgements</h2>
<p><strong>Funding:</strong> This study was supported by the Henan Provincial Science and Technology Research Project (Grant No. 232103810050) and the Henan Provincial Medical Science and Technology Research Program Joint Construction Project (Grant No. LHGJ20230469).</p>
<p><strong>Author contributions:</strong> Y.Z.: Conceptualization, methodology, investigation, data analysis, and original draft writing. C.L.: Resources, project administration, supervision, manuscript review, and manuscript revision. S.J.: Experimental validation, methodology support, and data curation. L.X.: Experimental validation, data interpretation, and visualization. Q.X.: Experimental assistance and manuscript editing. J.Y.: Project administration, supervision, funding acquisition, and manuscript revision.</p>
<p><strong>Competing interests:</strong> The authors declare that they have no competing interests.</p></section><section id="sec38"><h2 class="pmc_sec_title">Data Availability</h2>
<p>The datasets generated and/or analyzed during the current study are available from the corresponding author upon reasonable request.</p></section><section id="supplementary-material-1"><h2 class="pmc_sec_title">Supplementary Materials</h2>
<section class="sm xbox font-sm" id="supp-1"><div class="caption p">
<span>Supplementary 1</span><p>Figs. S1 to S4</p>
<p>Table S1</p>
</div>
<div class="media p"><div class="caption">
<a href="/articles/instance/12334082/bin/bmr.0232.f1.docx" data-ga-action="click_feat_suppl" class="usa-link">bmr.0232.f1.docx</a><sup> (7MB, docx) </sup>
</div></div></section></section><section id="ref-list1" class="ref-list"><h2 class="pmc_sec_title">References</h2>
<section id="ref-list1_sec2"><ul class="ref-list font-sm" style="list-style-type:none">
<li id="B1">
<span class="label">1.</span><cite>Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. 
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249.
</cite> [<a href="https://doi.org/10.3322/caac.21660" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33538338/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=CA%20Cancer%20J%20Clin&amp;title=Global%20cancer%20statistics%202020:%20GLOBOCAN%20estimates%20of%20incidence%20and%20mortality%20worldwide%20for%2036%20cancers%20in%20185%20countries&amp;volume=71&amp;issue=3&amp;publication_year=2021&amp;pages=209-249&amp;pmid=33538338&amp;doi=10.3322/caac.21660&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B2">
<span class="label">2.</span><cite>Tacar O, Dass CR. 
Doxorubicin-induced death in tumour cells and cardiomyocytes: Is autophagy the key to improving future clinical outcomes?
J Pharm Pharmacol. 2013;65(11):1577–1589.
</cite> [<a href="https://doi.org/10.1111/jphp.12144" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24102557/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Pharm%20Pharmacol&amp;title=Doxorubicin-induced%20death%20in%20tumour%20cells%20and%20cardiomyocytes:%20Is%20autophagy%20the%20key%20to%20improving%20future%20clinical%20outcomes?&amp;volume=65&amp;issue=11&amp;publication_year=2013&amp;pages=1577-1589&amp;pmid=24102557&amp;doi=10.1111/jphp.12144&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B3">
<span class="label">3.</span><cite>Turajlic S, Swanton C. 
Metastasis as an evolutionary process. Science. 2016;352(6282):169–175.
</cite> [<a href="https://doi.org/10.1126/science.aaf2784" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27124450/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Science&amp;title=Metastasis%20as%20an%20evolutionary%20process&amp;volume=352&amp;issue=6282&amp;publication_year=2016&amp;pages=169-175&amp;pmid=27124450&amp;doi=10.1126/science.aaf2784&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B4">
<span class="label">4.</span><cite>Park D, Jeon WJ, Yang C, Castillo DR. 
Advancing esophageal cancer treatment: Immunotherapy in neoadjuvant and adjuvant settings. Cancers (Basel). 2024;16(2):318.
</cite> [<a href="https://doi.org/10.3390/cancers16020318" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10813716/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38254805/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancers%20(Basel)&amp;title=Advancing%20esophageal%20cancer%20treatment:%20Immunotherapy%20in%20neoadjuvant%20and%20adjuvant%20settings&amp;volume=16&amp;issue=2&amp;publication_year=2024&amp;pages=318&amp;pmid=38254805&amp;doi=10.3390/cancers16020318&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B5">
<span class="label">5.</span><cite>Zhang X, Yu Y, Zhao H, Guo L, Dai K, Lv J. 
Mechanisms of tumor immunosuppressive microenvironment formation in esophageal cancer. World J Gastroenterol. 2024;30(16):2195–2208.
</cite> [<a href="https://doi.org/10.3748/wjg.v30.i16.2195" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11056912/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38690024/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=World%20J%20Gastroenterol&amp;title=Mechanisms%20of%20tumor%20immunosuppressive%20microenvironment%20formation%20in%20esophageal%20cancer&amp;volume=30&amp;issue=16&amp;publication_year=2024&amp;pages=2195-2208&amp;pmid=38690024&amp;doi=10.3748/wjg.v30.i16.2195&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B6">
<span class="label">6.</span><cite>Fucikova J, Kepp O, Kasikova L, Petroni G, Yamazaki T, Liu P, Zhao L, Spisek R, Kroemer G, Galluzzi L. 
Detection of immunogenic cell death and its relevance for cancer therapy. Cell Death Dis. 2020;11(11):1013.
</cite> [<a href="https://doi.org/10.1038/s41419-020-03221-2" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7691519/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33243969/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cell%20Death%20Dis&amp;title=Detection%20of%20immunogenic%20cell%20death%20and%20its%20relevance%20for%20cancer%20therapy&amp;volume=11&amp;issue=11&amp;publication_year=2020&amp;pages=1013&amp;pmid=33243969&amp;doi=10.1038/s41419-020-03221-2&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B7">
<span class="label">7.</span><cite>Chattopadhyay S, Liu Y, Fang Z, Lin C, Lin J, Yao B, Hu CJ. 
Synthetic immunogenic cell death mediated by intracellular delivery of STING agonist nanoshells enhances anticancer chemo-immunotherapy. Nano Lett. 2020;20(4):2246–2256.
</cite> [<a href="https://doi.org/10.1021/acs.nanolett.9b04094" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32160474/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nano%20Lett&amp;title=Synthetic%20immunogenic%20cell%20death%20mediated%20by%20intracellular%20delivery%20of%20STING%20agonist%20nanoshells%20enhances%20anticancer%20chemo-immunotherapy&amp;volume=20&amp;issue=4&amp;publication_year=2020&amp;pages=2246-2256&amp;pmid=32160474&amp;doi=10.1021/acs.nanolett.9b04094&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B8">
<span class="label">8.</span><cite>Deng Z, Chen S, Liu G, Zhu G. 
Unlocking the potential of platinum drugs: Organelle-targeted small-molecule platinum complexes for improved anticancer performance. RSC Chem Biol. 2023;4(12):1003–1013.
</cite> [<a href="https://doi.org/10.1039/d3cb00087g" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10685827/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38033725/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=RSC%20Chem%20Biol&amp;title=Unlocking%20the%20potential%20of%20platinum%20drugs:%20Organelle-targeted%20small-molecule%20platinum%20complexes%20for%20improved%20anticancer%20performance&amp;volume=4&amp;issue=12&amp;publication_year=2023&amp;pages=1003-1013&amp;pmid=38033725&amp;doi=10.1039/d3cb00087g&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B9">
<span class="label">9.</span><cite>Burris HA, Bakewell S, Bendell JC, Infante J, Jones SF, Spigel DR, Weiss GJ, Ramanathan RK, Ogden A, Von Hoff D. 
Safety and activity of IT-139, a ruthenium-based compound, in patients with advanced solid tumours: A first-in-human, open-label, dose-escalation phase I study with expansion cohort. ESMO Open. 2016;1(6):
Article e000154.
</cite> [<a href="https://doi.org/10.1136/esmoopen-2016-000154" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5548977/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28848672/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=ESMO%20Open&amp;title=Safety%20and%20activity%20of%20IT-139,%20a%20ruthenium-based%20compound,%20in%20patients%20with%20advanced%20solid%20tumours:%20A%20first-in-human,%20open-label,%20dose-escalation%20phase%20I%20study%20with%20expansion%20cohort&amp;volume=1&amp;issue=6&amp;publication_year=2016&amp;pages=Article%20e000154&amp;pmid=28848672&amp;doi=10.1136/esmoopen-2016-000154&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B10">
<span class="label">10.</span><cite>Zhai J, Gu X, Liu Y, Hu Y, Jiang Y, Zhang Z. 
Chemotherapeutic and targeted drugs-induced immunogenic cell death in cancer models and antitumor therapy: An update review. Front Pharmacol. 2023;14:1152934.
</cite> [<a href="https://doi.org/10.3389/fphar.2023.1152934" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10160433/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37153795/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Front%20Pharmacol&amp;title=Chemotherapeutic%20and%20targeted%20drugs-induced%20immunogenic%20cell%20death%20in%20cancer%20models%20and%20antitumor%20therapy:%20An%20update%20review&amp;volume=14&amp;publication_year=2023&amp;pages=1152934&amp;pmid=37153795&amp;doi=10.3389/fphar.2023.1152934&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B11">
<span class="label">11.</span><cite>Zhou Z, Zhou C, Liu J, Yuan Y, Yao C, Liu M, Deng L, Sun J, Chen Z, Wang L, et al. 
Tumor specific in situ synthesis of therapeutic agent for precision cancer therapy. J Nanobiotechnology. 2024;22(1):612.
</cite> [<a href="https://doi.org/10.1186/s12951-024-02825-6" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11465910/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39385273/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Nanobiotechnology&amp;title=Tumor%20specific%20in%C2%A0situ%20synthesis%20of%20therapeutic%20agent%20for%20precision%20cancer%20therapy&amp;volume=22&amp;issue=1&amp;publication_year=2024&amp;pages=612&amp;pmid=39385273&amp;doi=10.1186/s12951-024-02825-6&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B12">
<span class="label">12.</span><cite>Ma X, Liang A, Liu Y. 
Research progress on the relationship between lung cancer drug-resistance and microRNAs. J Cancer. 2019;10(27):6865–6875.
</cite> [<a href="https://doi.org/10.7150/jca.31952" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6909942/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31839821/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Cancer&amp;title=Research%20progress%20on%20the%20relationship%20between%20lung%20cancer%20drug-resistance%20and%20microRNAs&amp;volume=10&amp;issue=27&amp;publication_year=2019&amp;pages=6865-6875&amp;pmid=31839821&amp;doi=10.7150/jca.31952&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B13">
<span class="label">13.</span><cite>Li X, Chen W, Jin Y, Xue R, Su J, Mu Z, Li J, Jiang S. 
miR-142-5p enhances cisplatin-induced apoptosis in ovarian cancer cells by targeting multiple anti-apoptotic genes. Biochem Pharmacol. 2019;161:98–112.
</cite> [<a href="https://doi.org/10.1016/j.bcp.2019.01.009" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30639456/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Biochem%20Pharmacol&amp;title=miR-142-5p%20enhances%20cisplatin-induced%20apoptosis%20in%20ovarian%20cancer%20cells%20by%20targeting%20multiple%20anti-apoptotic%20genes&amp;volume=161&amp;publication_year=2019&amp;pages=98-112&amp;pmid=30639456&amp;doi=10.1016/j.bcp.2019.01.009&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B14">
<span class="label">14.</span><cite>Wang Z, Liu Z, Fang X, Yang H. 
MiR-142-5p suppresses tumorigenesis by targeting PIK3CA in non-small cell lung cancer. Cell Physiol Biochem. 2017;43(6):2505–2515.
</cite> [<a href="https://doi.org/10.1159/000484459" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29131028/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cell%20Physiol%20Biochem&amp;title=MiR-142-5p%20suppresses%20tumorigenesis%20by%20targeting%20PIK3CA%20in%20non-small%20cell%20lung%20cancer&amp;volume=43&amp;issue=6&amp;publication_year=2017&amp;pages=2505-2515&amp;pmid=29131028&amp;doi=10.1159/000484459&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B15">
<span class="label">15.</span><cite>Huang C, Huang C, Hsu T, Huang M, Fong I, Lee W, Liu S. 
Disruption of cancer metabolic SREBP1/miR-142-5p suppresses epithelial-mesenchymal transition and stemness in esophageal carcinoma. Cells. 2019;9(1):7.
</cite> [<a href="https://doi.org/10.3390/cells9010007" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7016574/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31861383/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cells&amp;title=Disruption%20of%20cancer%20metabolic%20SREBP1/miR-142-5p%20suppresses%20epithelial-mesenchymal%20transition%20and%20stemness%20in%20esophageal%20carcinoma&amp;volume=9&amp;issue=1&amp;publication_year=2019&amp;pages=7&amp;pmid=31861383&amp;doi=10.3390/cells9010007&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B16">
<span class="label">16.</span><cite>Boissenot T, Bordat A, Fattal E, Tsapis N. 
Ultrasound-triggered drug delivery for cancer treatment using drug delivery systems: From theoretical considerations to practical applications. J Control Release. 2016;241:144–163.
</cite> [<a href="https://doi.org/10.1016/j.jconrel.2016.09.026" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27667179/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Control%20Release&amp;title=Ultrasound-triggered%20drug%20delivery%20for%20cancer%20treatment%20using%20drug%20delivery%20systems:%20From%20theoretical%20considerations%20to%20practical%20applications&amp;volume=241&amp;publication_year=2016&amp;pages=144-163&amp;pmid=27667179&amp;doi=10.1016/j.jconrel.2016.09.026&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B17">
<span class="label">17.</span><cite>Su C, Ren X, Nie F, Li T, Lv W, Li H, Zhang Y. 
Current advances in ultrasound-combined nanobubbles for cancer-targeted therapy: A review of the current status and future perspectives. RSC Adv. 2021;11(21):12915–12928.
</cite> [<a href="https://doi.org/10.1039/d0ra08727k" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8697319/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35423829/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=RSC%20Adv&amp;title=Current%20advances%20in%20ultrasound-combined%20nanobubbles%20for%20cancer-targeted%20therapy:%20A%20review%20of%20the%20current%20status%20and%20future%20perspectives&amp;volume=11&amp;issue=21&amp;publication_year=2021&amp;pages=12915-12928&amp;pmid=35423829&amp;doi=10.1039/d0ra08727k&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B18">
<span class="label">18.</span><cite>Liao P, Tandarich LC, Hollenbeck PJ. 
ROS regulation of axonal mitochondrial transport is mediated by Ca<sup>2+</sup> and JNK in <em>Drosophila</em>. PLOS ONE. 2017;12(5):
Article e0178105.
</cite> [<a href="https://doi.org/10.1371/journal.pone.0178105" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5436889/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28542430/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=PLOS%20ONE&amp;title=ROS%20regulation%20of%20axonal%20mitochondrial%20transport%20is%20mediated%20by%20Ca2+%20and%20JNK%20in%20Drosophila&amp;volume=12&amp;issue=5&amp;publication_year=2017&amp;pages=Article%20e0178105&amp;pmid=28542430&amp;doi=10.1371/journal.pone.0178105&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B19">
<span class="label">19.</span><cite>Zhou Y, Jing S, Liu S, Shen X, Cai L, Zhu C, Zhao Y, Pang M. 
Double-activation of mitochondrial permeability transition pore opening via calcium overload and reactive oxygen species for cancer therapy. J Nanobiotechnology. 2022;20(1):188.
</cite> [<a href="https://doi.org/10.1186/s12951-022-01392-y" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9004178/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35413984/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Nanobiotechnology&amp;title=Double-activation%20of%20mitochondrial%20permeability%20transition%20pore%20opening%20via%20calcium%20overload%20and%20reactive%20oxygen%20species%20for%20cancer%20therapy&amp;volume=20&amp;issue=1&amp;publication_year=2022&amp;pages=188&amp;pmid=35413984&amp;doi=10.1186/s12951-022-01392-y&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B20">
<span class="label">20.</span><cite>Yan Y, Wei C, Zhang W, Cheng H, Liu J. 
Cross-talk between calcium and reactive oxygen species signaling. Acta Pharmacol Sin. 2006;27:821–826.
</cite> [<a href="https://doi.org/10.1111/j.1745-7254.2006.00390.x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/16787564/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Acta%20Pharmacol%20Sin&amp;title=Cross-talk%20between%20calcium%20and%20reactive%20oxygen%20species%20signaling&amp;volume=27&amp;publication_year=2006&amp;pages=821-826&amp;pmid=16787564&amp;doi=10.1111/j.1745-7254.2006.00390.x&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B21">
<span class="label">21.</span><cite>Gielecinska A, Kciuk M, Kontek R. 
The impact of calcium overload on cellular processes: Exploring calcicoptosis and its therapeutic potential in cancer. Int J Mol Sci. 2024;25(24):
Article 13727.
</cite> [<a href="https://doi.org/10.3390/ijms252413727" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11679949/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39769488/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Int%20J%20Mol%20Sci&amp;title=The%20impact%20of%20calcium%20overload%20on%20cellular%20processes:%20Exploring%20calcicoptosis%20and%20its%20therapeutic%20potential%20in%20cancer&amp;volume=25&amp;issue=24&amp;publication_year=2024&amp;pages=Article%2013727&amp;pmid=39769488&amp;doi=10.3390/ijms252413727&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B22">
<span class="label">22.</span><cite>Kaddour-Djebbar I, Choudhary V, Brooks C, Ghazaly T, Lakshmikanthan V, Dong Z, Kumar MV. 
Specific mitochondrial calcium overload induces mitochondrial fission in prostate cancer cells. Int J Oncol. 2010;36(6):1437.
</cite> [<a href="https://doi.org/10.3892/ijo_00000629" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20428767/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Int%20J%20Oncol&amp;title=Specific%20mitochondrial%20calcium%20overload%20induces%20mitochondrial%20fission%20in%20prostate%20cancer%20cells&amp;volume=36&amp;issue=6&amp;publication_year=2010&amp;pages=1437&amp;pmid=20428767&amp;doi=10.3892/ijo_00000629&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B23">
<span class="label">23.</span><cite>Brillo V, Chieregato L, Leanza L, Muccioli S, Costa R. 
Mitochondrial dynamics, ROS, and cell signaling: A blended overview. Life (Basel). 2021;11(4):
Article 332.
</cite> [<a href="https://doi.org/10.3390/life11040332" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8070048/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33920160/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Life%20(Basel)&amp;title=Mitochondrial%20dynamics,%20ROS,%20and%20cell%20signaling:%20A%20blended%20overview&amp;volume=11&amp;issue=4&amp;publication_year=2021&amp;pages=Article%20332&amp;pmid=33920160&amp;doi=10.3390/life11040332&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B24">
<span class="label">24.</span><cite>Romero-Garcia S, Prado-Garcia H. 
Mitochondrial calcium: Transport and modulation of cellular processes in homeostasis and cancer (review). Int J Oncol. 2019;54(4):1155–1167.
</cite> [<a href="https://doi.org/10.3892/ijo.2019.4696" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30720054/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Int%20J%20Oncol&amp;title=Mitochondrial%20calcium:%20Transport%20and%20modulation%20of%20cellular%20processes%20in%20homeostasis%20and%20cancer%20(review)&amp;volume=54&amp;issue=4&amp;publication_year=2019&amp;pages=1155-1167&amp;pmid=30720054&amp;doi=10.3892/ijo.2019.4696&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B25">
<span class="label">25.</span><cite>Green A, Hossain T, Eckmann DM. 
Mitochondrial dynamics involves molecular and mechanical events in motility, fusion and fission. Front Cell Dev Biol. 2022;10:1010232.
</cite> [<a href="https://doi.org/10.3389/fcell.2022.1010232" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9626967/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36340034/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Front%20Cell%20Dev%20Biol&amp;title=Mitochondrial%20dynamics%20involves%20molecular%20and%20mechanical%20events%20in%20motility,%20fusion%20and%20fission&amp;volume=10&amp;publication_year=2022&amp;pages=1010232&amp;pmid=36340034&amp;doi=10.3389/fcell.2022.1010232&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B26">
<span class="label">26.</span><cite>Park S, Won J, Hwang I, Hong S, Lee HK, Yu J. 
Defective mitochondrial fission augments NLRP3 inflammasome activation. Sci Rep. 2015;5:15489.
</cite> [<a href="https://doi.org/10.1038/srep15489" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4614538/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26489382/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Sci%20Rep&amp;title=Defective%20mitochondrial%20fission%20augments%20NLRP3%20inflammasome%20activation&amp;volume=5&amp;publication_year=2015&amp;pages=15489&amp;pmid=26489382&amp;doi=10.1038/srep15489&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B27">
<span class="label">27.</span><cite>Shen R, Liu D, Wang X, Guo Z, Sun H, Song Y, Wang D. 
DNA damage and activation of cGAS/STING pathway induce tumor microenvironment remodeling. Front Cell Dev Biol. 2021;9:
Article 828657.
</cite> [<a href="https://doi.org/10.3389/fcell.2021.828657" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8900217/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35265630/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Front%20Cell%20Dev%20Biol&amp;title=DNA%20damage%20and%20activation%20of%20cGAS/STING%20pathway%20induce%20tumor%20microenvironment%20remodeling&amp;volume=9&amp;publication_year=2021&amp;pages=Article%20828657&amp;pmid=35265630&amp;doi=10.3389/fcell.2021.828657&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B28">
<span class="label">28.</span><cite>Li J, Xi A, Qiao H, Liu Z. 
Ultrasound-mediated diagnostic imaging and advanced treatment with multifunctional micro/nanobubbles. Cancer Lett. 2020;475:92–98.
</cite> [<a href="https://doi.org/10.1016/j.canlet.2020.01.028" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32032678/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Lett&amp;title=Ultrasound-mediated%20diagnostic%20imaging%20and%20advanced%20treatment%20with%20multifunctional%20micro/nanobubbles&amp;volume=475&amp;publication_year=2020&amp;pages=92-98&amp;pmid=32032678&amp;doi=10.1016/j.canlet.2020.01.028&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B29">
<span class="label">29.</span><cite>Tian J, Wan S, Tian J, Liu L, Xia J, Hu Y, Yang Z, Zhao H, Wang H, Guo Y, et al. 
Anti-HER2 scFv-nCytc-modified lipid-encapsulated oxygen nanobubbles prepared with bulk nanobubble water for inducing apoptosis and improving photodynamic therapy. Small. 2023;19(23):
Article e2206091.
</cite> [<a href="https://doi.org/10.1002/smll.202206091" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36855335/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Small&amp;title=Anti-HER2%20scFv-nCytc-modified%20lipid-encapsulated%20oxygen%20nanobubbles%20prepared%20with%20bulk%20nanobubble%20water%20for%20inducing%20apoptosis%20and%20improving%20photodynamic%20therapy&amp;volume=19&amp;issue=23&amp;publication_year=2023&amp;pages=Article%20e2206091&amp;pmid=36855335&amp;doi=10.1002/smll.202206091&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B30">
<span class="label">30.</span><cite>Capolla S, Argenziano M, Bozzer S, D’Agaro T, Bittolo T, De Leo L, Not T, Busato D, Dal Bo M, Toffoli G, et al. 
Targeted chitosan nanobubbles as a strategy to down-regulate microRNA-17 into B-cell lymphoma models. Front Immunol. 2023;14:1200310.
</cite> [<a href="https://doi.org/10.3389/fimmu.2023.1200310" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10285521/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37359561/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Front%20Immunol&amp;title=Targeted%20chitosan%20nanobubbles%20as%20a%20strategy%20to%20down-regulate%20microRNA-17%20into%20B-cell%20lymphoma%20models&amp;volume=14&amp;publication_year=2023&amp;pages=1200310&amp;pmid=37359561&amp;doi=10.3389/fimmu.2023.1200310&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B31">
<span class="label">31.</span><cite>Su C, Ren X, Yang F, Li B, Wu H, Li H, Nie F. 
Ultrasound-sensitive siRNA-loaded nanobubbles fabrication and antagonism in drug resistance for NSCLC. Drug Deliv. 2022;29(1):99–110.
</cite> [<a href="https://doi.org/10.1080/10717544.2021.2021321" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8725955/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34964410/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Drug%20Deliv&amp;title=Ultrasound-sensitive%20siRNA-loaded%20nanobubbles%20fabrication%20and%20antagonism%20in%20drug%20resistance%20for%20NSCLC&amp;volume=29&amp;issue=1&amp;publication_year=2022&amp;pages=99-110&amp;pmid=34964410&amp;doi=10.1080/10717544.2021.2021321&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B32">
<span class="label">32.</span><cite>Wang L, Guan R, Xie L, Liao X, Xiong K, Rees TW, Chen Y, Ji L, Chao H. 
An ER-targeting iridium(III) complex that induces immunogenic cell death in non-small-cell lung cancer. Angew Chem Int Ed Engl. 2021;60(9):4657–4665.
</cite> [<a href="https://doi.org/10.1002/anie.202013987" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33217194/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Angew%20Chem%20Int%20Ed%20Engl&amp;title=An%20ER-targeting%20iridium(III)%20complex%20that%20induces%20immunogenic%20cell%20death%20in%20non-small-cell%20lung%20cancer&amp;volume=60&amp;issue=9&amp;publication_year=2021&amp;pages=4657-4665&amp;pmid=33217194&amp;doi=10.1002/anie.202013987&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B33">
<span class="label">33.</span><cite>Newman LE, Shadel GS. 
Mitochondrial DNA release in innate immune signaling. Annu Rev Biochem. 2023;92:299–332.
</cite> [<a href="https://doi.org/10.1146/annurev-biochem-032620-104401" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11058562/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37001140/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Annu%20Rev%20Biochem&amp;title=Mitochondrial%20DNA%20release%20in%20innate%20immune%20signaling&amp;volume=92&amp;publication_year=2023&amp;pages=299-332&amp;pmid=37001140&amp;doi=10.1146/annurev-biochem-032620-104401&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B34">
<span class="label">34.</span><cite>Feng X, Lin T, Chen D, Li Z, Yang Q, Tian H, Xiao Y, Lin M, Liang M, Guo W, et al. 
Mitochondria-associated ER stress evokes immunogenic cell death through the ROS-PERK-eIF2α pathway under PTT/CDT combined therapy. Acta Biomater. 2023;160:211–224.
</cite> [<a href="https://doi.org/10.1016/j.actbio.2023.02.011" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36792045/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Acta%20Biomater&amp;title=Mitochondria-associated%20ER%20stress%20evokes%20immunogenic%20cell%20death%20through%20the%20ROS-PERK-eIF2%CE%B1%20pathway%20under%20PTT/CDT%20combined%20therapy&amp;volume=160&amp;publication_year=2023&amp;pages=211-224&amp;pmid=36792045&amp;doi=10.1016/j.actbio.2023.02.011&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B35">
<span class="label">35.</span><cite>Jiang H, Fu H, Guo Y, Hu P, Shi J. 
Evoking tumor associated macrophages by mitochondria-targeted magnetothermal immunogenic cell death for cancer immunotherapy. Biomaterials. 2022;289:
Article 121799.
</cite> [<a href="https://doi.org/10.1016/j.biomaterials.2022.121799" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36152515/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Biomaterials&amp;title=Evoking%20tumor%20associated%20macrophages%20by%20mitochondria-targeted%20magnetothermal%20immunogenic%20cell%20death%20for%20cancer%20immunotherapy&amp;volume=289&amp;publication_year=2022&amp;pages=Article%20121799&amp;pmid=36152515&amp;doi=10.1016/j.biomaterials.2022.121799&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B36">
<span class="label">36.</span><cite>Bononi A, Giorgi C, Patergnani S, Larson D, Verbruggen K, Tanji M, Pellegrini L, Signorato V, Olivetto F, Pastorino S, et al. 
BAP1 regulates IP3R3-mediated Ca<sup>2+</sup> flux to mitochondria suppressing cell transformation. Nature. 2017;546:549–553.
</cite> [<a href="https://doi.org/10.1038/nature22798" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5581194/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28614305/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nature&amp;title=BAP1%20regulates%20IP3R3-mediated%20Ca2+%20flux%20to%20mitochondria%20suppressing%20cell%20transformation&amp;volume=546&amp;publication_year=2017&amp;pages=549-553&amp;pmid=28614305&amp;doi=10.1038/nature22798&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B37">
<span class="label">37.</span><cite>Fu W, Liu Y, Yin H. 
Mitochondrial dynamics: Biogenesis, fission, fusion, and mitophagy in the regulation of stem cell behaviors. Stem Cells Int. 2019;2019:9757201.
</cite> [<a href="https://doi.org/10.1155/2019/9757201" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6476046/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31089338/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Stem%20Cells%20Int&amp;title=Mitochondrial%20dynamics:%20Biogenesis,%20fission,%20fusion,%20and%20mitophagy%20in%20the%20regulation%20of%20stem%20cell%20behaviors&amp;volume=2019&amp;publication_year=2019&amp;pages=9757201&amp;pmid=31089338&amp;doi=10.1155/2019/9757201&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B38">
<span class="label">38.</span><cite>Tawbi HA, Forsyth PA, Algazi A, Hamid O, Hodi FS, Moschos SJ, Khushalani NI, Lewis K, Lao CD, Postow MA, et al. 
Combined nivolumab and ipilimumab in melanoma metastatic to the brain. N Engl J Med. 2018;379(8):722–730.
</cite> [<a href="https://doi.org/10.1056/NEJMoa1805453" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8011001/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30134131/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&amp;title=Combined%20nivolumab%20and%20ipilimumab%20in%20melanoma%20metastatic%20to%20the%20brain&amp;volume=379&amp;issue=8&amp;publication_year=2018&amp;pages=722-730&amp;pmid=30134131&amp;doi=10.1056/NEJMoa1805453&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B39">
<span class="label">39.</span><cite>Li B, Jin J, Guo D, Tao Z, Hu X. 
Immune checkpoint inhibitors combined with targeted therapy: The recent advances and future potentials. Cancers. 2023;15(10):2858.
</cite> [<a href="https://doi.org/10.3390/cancers15102858" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10216018/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37345194/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancers&amp;title=Immune%20checkpoint%20inhibitors%20combined%20with%20targeted%20therapy:%20The%20recent%20advances%20and%20future%20potentials&amp;volume=15&amp;issue=10&amp;publication_year=2023&amp;pages=2858&amp;pmid=37345194&amp;doi=10.3390/cancers15102858&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B40">
<span class="label">40.</span><cite>Latchman YE, Liang SC, Wu Y, Chernova T, Sobel RA, Klemm M, Kuchroo VK, Freeman GJ, Sharpe AH. 
PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells. Proc Natl Acad Sci USA. 2004;101(29):10691–10696.
</cite> [<a href="https://doi.org/10.1073/pnas.0307252101" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC489996/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/15249675/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Proc%20Natl%20Acad%20Sci%20USA&amp;title=PD-L1-deficient%20mice%20show%20that%20PD-L1%20on%20T%20cells,%20antigen-presenting%20cells,%20and%20host%20tissues%20negatively%20regulates%20T%20cells&amp;volume=101&amp;issue=29&amp;publication_year=2004&amp;pages=10691-10696&amp;pmid=15249675&amp;doi=10.1073/pnas.0307252101&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B41">
<span class="label">41.</span><cite>Yee D, Shah KM, Coles MC, Sharp TV, Lagos D. 
MicroRNA-155 induction via TNF-alpha and IFN-gamma suppresses expression of programmed death ligand-1 (PD-L1) in human primary cells. J Biol Chem. 2017;292(50):20683–20693.
</cite> [<a href="https://doi.org/10.1074/jbc.M117.809053" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5733604/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29066622/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Biol%20Chem&amp;title=MicroRNA-155%20induction%20via%20TNF-alpha%20and%20IFN-gamma%20suppresses%20expression%20of%20programmed%20death%20ligand-1%20(PD-L1)%20in%20human%20primary%20cells&amp;volume=292&amp;issue=50&amp;publication_year=2017&amp;pages=20683-20693&amp;pmid=29066622&amp;doi=10.1074/jbc.M117.809053&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B42">
<span class="label">42.</span><cite>Cortez MA, Ivan C, Valdecanas D, Wang X, Peltier HJ, Ye Y, Araujo L, Carbone DP, Shilo K, Giri DK, et al. 
PDL1 regulation by p53 via miR-34. J Natl Cancer Inst. 2016;108(1).</cite> [<a href="https://doi.org/10.1093/jnci/djv303" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4862407/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26577528/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Natl%20Cancer%20Inst&amp;title=PDL1%20regulation%20by%20p53%20via%20miR-34&amp;volume=108&amp;issue=1&amp;publication_year=2016&amp;pmid=26577528&amp;doi=10.1093/jnci/djv303&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B43">
<span class="label">43.</span><cite>Liu Y, Xie Q, Ma Y, Lin C, Li J, Hu B, Liu C, Zhao Y. 
Nanobubbles containing PD-L1 ab and miR-424 mediated PD-L1 blockade, and its expression inhibition to enable and potentiate hepatocellular carcinoma immunotherapy in mice. Int J Pharm. 2022;629:
Article 122352.
</cite> [<a href="https://doi.org/10.1016/j.ijpharm.2022.122352" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36374798/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Int%20J%20Pharm&amp;title=Nanobubbles%20containing%20PD-L1%20ab%20and%20miR-424%20mediated%20PD-L1%20blockade,%20and%20its%20expression%20inhibition%20to%20enable%20and%20potentiate%20hepatocellular%20carcinoma%20immunotherapy%20in%20mice&amp;volume=629&amp;publication_year=2022&amp;pages=Article%20122352&amp;pmid=36374798&amp;doi=10.1016/j.ijpharm.2022.122352&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B44">
<span class="label">44.</span><cite>Liu Z, Ren Y, Weng S, Xu H, Li L, Han X. 
A new trend in cancer treatment: The combination of epigenetics and immunotherapy. Front Immunol. 2022;13:
Article 809761.
</cite> [<a href="https://doi.org/10.3389/fimmu.2022.809761" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8818678/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35140720/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Front%20Immunol&amp;title=A%20new%20trend%20in%20cancer%20treatment:%20The%20combination%20of%20epigenetics%20and%20immunotherapy&amp;volume=13&amp;publication_year=2022&amp;pages=Article%20809761&amp;pmid=35140720&amp;doi=10.3389/fimmu.2022.809761&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B45">
<span class="label">45.</span><cite>Smyth MJ, Ngiow SF, Ribas A, Teng MWL. 
Combination cancer immunotherapies tailored to the tumour microenvironment. Nat Rev Clin Oncol. 2016;13(3):143–158.
</cite> [<a href="https://doi.org/10.1038/nrclinonc.2015.209" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26598942/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nat%20Rev%20Clin%20Oncol&amp;title=Combination%20cancer%20immunotherapies%20tailored%20to%20the%20tumour%20microenvironment&amp;volume=13&amp;issue=3&amp;publication_year=2016&amp;pages=143-158&amp;pmid=26598942&amp;doi=10.1038/nrclinonc.2015.209&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B46">
<span class="label">46.</span><cite>Salas-Benito D, Perez-Gracia JL, Ponz-Sarvise M, Rodriguez-Ruiz ME, Martinez-Forero I, Castanon E, Lopez-Picazo JM, Sanmamed MF, Melero I. 
Paradigms on immunotherapy combinations with chemotherapy. Cancer Discov. 2021;11(6):1353–1367.
</cite> [<a href="https://doi.org/10.1158/2159-8290.CD-20-1312" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33712487/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Discov&amp;title=Paradigms%20on%20immunotherapy%20combinations%20with%20chemotherapy&amp;volume=11&amp;issue=6&amp;publication_year=2021&amp;pages=1353-1367&amp;pmid=33712487&amp;doi=10.1158/2159-8290.CD-20-1312&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B47">
<span class="label">47.</span><cite>Fang K, Yuan S, Zhang X, Zhang J, Sun S, Li X. 
Regulation of immunogenic cell death and potential applications in cancer therapy. Front Immunol. 2025;16:1571212.
</cite> [<a href="https://doi.org/10.3389/fimmu.2025.1571212" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11979251/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/40207233/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Front%20Immunol&amp;title=Regulation%20of%20immunogenic%20cell%20death%20and%20potential%20applications%20in%20cancer%20therapy&amp;volume=16&amp;publication_year=2025&amp;pages=1571212&amp;pmid=40207233&amp;doi=10.3389/fimmu.2025.1571212&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B48">
<span class="label">48.</span><cite>Jia L, Xi Q, Wang H, Zhang Z, Liu H, Cheng Y, Guo X, Zhang J, Zhang Q, Zhang L, et al. 
miR-142-5p regulates tumor cell PD-L1 expression and enhances anti-tumor immunity. Biochem Biophys Res Commun. 2017;488(2):425–431.
</cite> [<a href="https://doi.org/10.1016/j.bbrc.2017.05.074" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28511795/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Biochem%20Biophys%20Res%20Commun&amp;title=miR-142-5p%20regulates%20tumor%20cell%20PD-L1%20expression%20and%20enhances%20anti-tumor%20immunity&amp;volume=488&amp;issue=2&amp;publication_year=2017&amp;pages=425-431&amp;pmid=28511795&amp;doi=10.1016/j.bbrc.2017.05.074&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B49">
<span class="label">49.</span><cite>Lin X, Kang K, Chen P, Zeng Z, Li G, Xiong W, Yi M, Xiang B. 
Regulatory mechanisms of PD-1/PD-L1 in cancers. Mol Cancer. 2024;23(1):108.
</cite> [<a href="https://doi.org/10.1186/s12943-024-02023-w" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11102195/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38762484/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Mol%20Cancer&amp;title=Regulatory%20mechanisms%20of%20PD-1/PD-L1%20in%20cancers&amp;volume=23&amp;issue=1&amp;publication_year=2024&amp;pages=108&amp;pmid=38762484&amp;doi=10.1186/s12943-024-02023-w&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B50">
<span class="label">50.</span><cite>Martin-Broto J, Diaz-Beveridge R, Moura D, Ramos R, Martinez-Trufero J, Carrasco I, Sebio A, Gonzalez-Billalabeitia E, Gutierrez A, Fernandez-Jara J, et al. 
Phase Ib study for the combination of doxorubicin, dacarbazine, and nivolumab as the upfront treatment in patients with advanced leiomyosarcoma: A study by the Spanish sarcoma group (GEIS). J Clin Oncol. 2025;43(3):297–307.
</cite> [<a href="https://doi.org/10.1200/JCO.24.00358" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39356980/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Clin%20Oncol&amp;title=Phase%20Ib%20study%20for%20the%20combination%20of%20doxorubicin,%20dacarbazine,%20and%20nivolumab%20as%20the%20upfront%20treatment%20in%20patients%20with%20advanced%20leiomyosarcoma:%20A%20study%20by%20the%20Spanish%20sarcoma%20group%20(GEIS)&amp;volume=43&amp;issue=3&amp;publication_year=2025&amp;pages=297-307&amp;pmid=39356980&amp;doi=10.1200/JCO.24.00358&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
</ul></section></section><section id="_ad93_" lang="en" class="associated-data"><h2 class="pmc_sec_title">Associated Data</h2>
<p class="font-secondary"><em>This section collects any data citations, data availability statements, or supplementary materials included in this article.</em></p>
<section id="_adsm93_" lang="en" class="supplementary-materials"><h3 class="pmc_sec_title">Supplementary Materials</h3>
<section class="sm xbox font-sm" id="db_ds_supplementary-material1_reqid_"><div class="caption p">
<span>Supplementary 1</span><p>Figs. S1 to S4</p>
<p>Table S1</p>
</div>
<div class="media p"><div class="caption">
<a href="/articles/instance/12334082/bin/bmr.0232.f1.docx" data-ga-action="click_feat_suppl" class="usa-link">bmr.0232.f1.docx</a><sup> (7MB, docx) </sup>
</div></div></section></section><section id="_adda93_" lang="en" class="data-availability-statement"><h3 class="pmc_sec_title">Data Availability Statement</h3>
<p>The datasets generated and/or analyzed during the current study are available from the corresponding author upon reasonable request.</p></section></section></section><footer class="p courtesy-note font-secondary font-sm text-center"><hr class="headless">
<p>Articles from Biomaterials Research are provided here courtesy of <strong>AAAS Science Partner Journal Program</strong></p></footer></section></article>

                      

                    </main>
                </div>
            </div>
        </div>

        



<!-- Secondary navigation placeholder -->
<div class="pmc-sidenav desktop:grid-col-4 display-flex">
    <section class="pmc-sidenav__container" aria-label="Article resources and navigation">
        <button type="button" class="usa-button pmc-sidenav__container__close usa-button--unstyled">
            <img src="/static/img/usa-icons/close.svg" role="img" alt="Close" />
        </button>
    <div class="display-none desktop:display-block">
       <section class="margin-top-4 desktop:margin-top-0">
              <h2 class="margin-top-0">ACTIONS</h2>
           <ul class="usa-list usa-list--unstyled usa-list--actions">
               
               <li>
                     <a
                             href="https://doi.org/10.34133/bmr.0232"
                             class="usa-button usa-button--outline width-24 font-xs display-inline-flex flex-align-center flex-justify-start padding-left-1"
                             target="_blank"
                             rel="noreferrer noopener"
                             data-ga-category="actions"
                             data-ga-action="click"
                             data-ga-label="publisher_link_desktop"
                     >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#launch"></use>
                         </svg>
                         <span class="display-inline-flex flex-justify-center flex-1 padding-right-2">View on publisher site</span>
                     </a>
               </li>
               
               
               <li>
                    <a
                            href="pdf/bmr.0232.pdf"
                            class="usa-button usa-button--outline width-24 display-inline-flex flex-align-center flex-justify-start padding-left-1"
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="pdf_download_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#file_download"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1">PDF (26.0 MB)</span>
                    </a>
               </li>
               
                
               <li>
                   <button role="button" class="usa-button width-24 citation-dialog-trigger display-inline-flex flex-align-center flex-justify-start padding-left-1"
                        aria-label="Open dialog with citation text in different styles"
                        data-ga-category="actions"
                        data-ga-action="open"
                        data-ga-label="cite_desktop"
                        data-all-citations-url="/resources/citations/12334082/"
                        data-citation-style="nlm"
                        data-download-format-link="/resources/citations/12334082/export/"
                    >
                        <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                        </svg>
                       <span class="display-inline-flex flex-justify-center flex-1 button-label">Cite</span>
                    </button>
               </li>
                
               <li>

                        <button class="usa-button width-24 collections-dialog-trigger collections-button display-inline-flex flex-align-center flex-justify-start padding-left-1 collections-button-empty"
                              aria-label="Save article in MyNCBI collections."
                              data-ga-category="actions"
                              data-ga-action="click"
                              data-ga-label="collections_button_desktop"
                              data-collections-open-dialog-enabled="false"
                              data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12334082%2F%3Freport%3Dclassic%23open-collections-dialog"
                              data-in-collections="false">
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                            <span class="display-inline-flex flex-justify-center flex-1">Collections</span>
                       </button>
               </li>
               <li class="pmc-permalink">
                    <button
                            type="button"
                            class="usa-button width-24 display-inline-flex flex-align-center flex-justify padding-left-1 shadow-none"
                            aria-label="Show article permalink"
                            aria-expanded="false"
                            aria-haspopup="true"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="permalink_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#share"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1 button-label">Permalink</span>
                    </button>
                   

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12334082/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
               </li>
           </ul>
       </section>
     </div>

        <section class="pmc-resources margin-top-6 desktop:margin-top-4" data-page-path="/articles/PMC12334082/">
            <h2 class="margin-top-0">RESOURCES</h2>
            
                <div class="usa-accordion usa-accordion--multiselectable" data-allow-multiple>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-similar-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_similar_articles"
                        data-ga-label="/articles/PMC12334082/"
                        data-action-open="open_similar_articles"
                        data-action-close="close_similar_articles"
                        >
                            Similar articles
                        </button>
                    </h3>
                    <div
                            id="resources-similar-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/similar-article-links/40785846/"
                            
                    >
                        
                    </div>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-cited-by-other-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_cited_by"
                        data-ga-label="/articles/PMC12334082/"
                        data-action-open="open_cited_by"
                        data-action-close="close_cited_by"
                        >
                             Cited by other articles
                        </button>
                    </h3>
                    <div
                            id="resources-cited-by-other-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/cited-by-links/40785846/"
                            
                    >
                          
                    </div>
                    
                        <h3 class="usa-accordion__heading">
                            <button
                            type="button"
                            class="usa-accordion__button"
                            aria-expanded="false"
                            aria-controls="resources-links-to-ncbi-databases"
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/articles/PMC12334082/"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                            >
                                 Links to NCBI Databases
                            </button>
                        </h3>
                        <div
                                id="resources-links-to-ncbi-databases"
                                class="usa-accordion__content usa-prose"
                                data-source-url="/resources/db-links/12334082/"
                        >
                        </div>
                    
                    
                </div>
            
        </section>


        <section
        class="usa-in-page-nav usa-in-page-nav--wide margin-top-6 desktop:margin-top-4"
        data-title-text="On this page"
        data-title-heading-level="h2"
        data-scroll-offset="0"
        data-root-margin="-10% 0px -80% 0px"
        data-main-content-selector="main"
        data-threshold="1"
        hidden
        ></section>
    </section>
</div>


        

<div class="overlay" role="dialog" aria-label="Citation Dialog" hidden>
    <div class="dialog citation-dialog" aria-hidden="true">
        <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
            <h2 class="usa-modal__heading margin-0">Cite</h2>
             <button type="button" class="usa-button usa-button--unstyled close-overlay text-black width-auto"  tabindex="1">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
             </button>
        </div>

        

<div class="citation-text-block">
  <div class="citation-text margin-bottom-2"></div>
  <ul class="usa-list usa-list--unstyled display-inline-flex flex-justify width-full flex-align-center">
      <li>
        <button
          class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center copy-button dialog-focus"
          data-ga-category="save_share"
          data-ga-action="cite"
          data-ga-label="copy"
          tabindex="2">
            <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                <use xlink:href="/static/img/sprite.svg#content_copy"></use>
            </svg>
            <span>Copy</span>
        </button>
      </li>
      <li>
          <a
              href="#"
              role="button"
              class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center export-button"
              data-ga-category="save_share"
              data-ga-action="cite"
              data-ga-label="download"
              title="Download a file for external citation management software"
              tabindex="3">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                </svg>
                <span class="display-none mobile-lg:display-inline">Download .nbib</span>
                <span class="display-inline mobile-lg:display-none">.nbib</span>
            </a>
      </li>
      <li>
          

<div class="display-inline-flex flex-align-center">
  <label class="usa-label margin-top-0">Format:</label>
  <select aria-label="Format" class="usa-select citation-style-selector padding-1 margin-top-0 border-0 padding-right-4" tabindex="4" >
    
      <option data-style-url-name="ama"
              value="AMA"
              >
        AMA
      </option>
    
      <option data-style-url-name="apa"
              value="APA"
              >
        APA
      </option>
    
      <option data-style-url-name="mla"
              value="MLA"
              >
        MLA
      </option>
    
      <option data-style-url-name="nlm"
              value="NLM"
              selected="selected">
        NLM
      </option>
    
  </select>
</div>
      </li>
  </ul>
</div>
    </div>
</div>

        <div class="overlay" role="dialog" hidden>
  <div id="collections-action-dialog" class="dialog collections-dialog" aria-hidden="true">
   <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
        <h2 class="usa-modal__heading margin-0">Add to Collections</h2>
    </div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="usa-form maxw-full collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/list-existing-collections/"
      data-add-to-existing-collection-url="/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

    <input type="hidden" name="csrfmiddlewaretoken" value="jGvMIlq8Un7pBtYnj9KbGH3X6wVmxsUFzVElNp5SMolIf3IoGJJkXYkfpFnh6rUD">

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-new"
            class="usa-radio__input usa-radio__input--tile collections-new  margin-top-0"
            name="collections"
            value="new"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_new" />
            <label class="usa-radio__label" for="collections-action-dialog-new">Create a new collection</label>
        </div>
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-existing"
            class="usa-radio__input usa-radio__input--tile collections-existing"
            name="collections"
            value="existing"
            checked="true"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_existing" />
            <label class="usa-radio__label" for="collections-action-dialog-existing">Add to an existing collection</label>
        </div>
    </fieldset>

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="action-panel-control-wrap new-collections-controls">
           <label for="collections-action-dialog-add-to-new" class="usa-label margin-top-0">
                Name your collection
               <abbr title="required" class="usa-hint usa-hint--required text-no-underline">*</abbr>
          </label>
          <input
            type="text"
            name="add-to-new-collection"
            id="collections-action-dialog-add-to-new"
            class="usa-input collections-action-add-to-new"
            pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
            maxlength=""
            data-ga-category="collections_button"
            data-ga-action="create_collection"
            data-ga-label="non_favorties_collection"
            required
          />
        </div>
        <div class="action-panel-control-wrap existing-collections-controls">
             <label for="collections-action-dialog-add-to-existing" class="usa-label margin-top-0">
                Choose a collection
              </label>
              <select id="collections-action-dialog-add-to-existing"
                      class="usa-select collections-action-add-to-existing"
                      data-ga-category="collections_button"
                      data-ga-action="select_collection"
                      data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
              </select>
              <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
                Unable to load your collection due to an error<br>
                <a href="#">Please try again</a>
              </div>
        </div>
    </fieldset>

    <div class="display-inline-flex">
        <button class="usa-button margin-top-0 action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
          Add
        </button>
        <button class="usa-button usa-button--outline margin-top-0 action-panel-cancel"
                aria-label="Close 'Add to Collections' panel"
                ref="linksrc=close_collections_panel"
                data-ga-category="collections_button"
                data-ga-action="click"
                data-ga-label="cancel">
          Cancel
        </button>
    </div>
</form>
    </div>
  </div>
</div>

        

      </div>
    </div>
  </div>



        
    
    

<footer class="ncbi-footer ncbi-dark-background " >
    
        <div class="ncbi-footer__icon-section">
            <div class="ncbi-footer__social-header">
                Follow NCBI
            </div>

            <div class="grid-container ncbi-footer__ncbi-social-icons-container">
                
                    <a href="https://twitter.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="40"
                             height="40"
                             viewBox="0 0 40 40"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on X (formerly known as Twitter)</span>
                    </a>
                

                
                    <a href="https://www.facebook.com/ncbi.nlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="16"
                             height="29"
                             focusable="false"
                             aria-hidden="true"
                             viewBox="0 0 16 29"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg">
                            <path d="M3.8809 21.4002C3.8809 19.0932 3.8809 16.7876 3.8809 14.478C3.8809 14.2117 3.80103 14.1452 3.54278 14.1492C2.53372 14.1638 1.52334 14.1492 0.514288 14.1598C0.302626 14.1598 0.248047 14.0972 0.248047 13.8936C0.256034 12.4585 0.256034 11.0239 0.248047 9.58978C0.248047 9.37013 0.302626 9.30224 0.528931 9.3049C1.53798 9.31688 2.54837 9.3049 3.55742 9.31555C3.80103 9.31555 3.8809 9.26097 3.87957 9.00272C3.87158 8.00565 3.85428 7.00592 3.90753 6.00884C3.97142 4.83339 4.31487 3.73115 5.04437 2.78467C5.93095 1.63318 7.15699 1.09005 8.56141 0.967577C10.5582 0.79319 12.555 0.982221 14.5518 0.927641C14.7102 0.927641 14.7462 0.99287 14.7449 1.13664C14.7449 2.581 14.7449 4.02668 14.7449 5.47104C14.7449 5.67604 14.6517 5.68669 14.4946 5.68669C13.4523 5.68669 12.4113 5.68669 11.3703 5.68669C10.3506 5.68669 9.92057 6.10868 9.90593 7.13904C9.89661 7.7647 9.91525 8.39303 9.89794 9.01869C9.88995 9.26364 9.96583 9.31822 10.2015 9.31688C11.7204 9.30623 13.2393 9.31688 14.7595 9.3049C15.0257 9.3049 15.0723 9.3728 15.0444 9.62439C14.89 10.9849 14.7515 12.3467 14.6144 13.7085C14.5691 14.1571 14.5785 14.1585 14.1458 14.1585C12.8386 14.1585 11.5313 14.1665 10.2254 14.1518C9.95119 14.1518 9.89794 14.2317 9.89794 14.4899C9.90593 19.0799 9.89794 23.6752 9.91125 28.2612C9.91125 28.5674 9.8407 28.646 9.53186 28.6433C7.77866 28.6273 6.02414 28.6366 4.27094 28.634C3.82499 28.634 3.87158 28.6992 3.87158 28.22C3.87602 25.9472 3.87913 23.6739 3.8809 21.4002Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on Facebook</span>
                    </a>
                

                
                    <a href="https://www.linkedin.com/company/ncbinlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="25"
                             height="23"
                             viewBox="0 0 26 24"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M14.6983 9.98423C15.6302 9.24808 16.5926 8.74754 17.6762 8.51991C19.673 8.09126 21.554 8.30824 23.1262 9.7526C24.2351 10.7723 24.7529 12.1115 25.0165 13.5612C25.1486 14.3363 25.2105 15.1218 25.2015 15.9081C25.2015 18.3043 25.2015 20.6898 25.2082 23.0806C25.2082 23.3468 25.1549 23.444 24.8621 23.4414C23.1297 23.4272 21.3992 23.4272 19.6704 23.4414C19.4041 23.4414 19.3429 23.3588 19.3442 23.1019C19.3535 20.5194 19.3442 17.9368 19.3442 15.3543C19.3442 14.0005 18.3258 12.9448 17.0266 12.9488C15.7273 12.9528 14.6983 14.0071 14.6983 15.361C14.6983 17.9328 14.6917 20.5047 14.6983 23.0753C14.6983 23.3708 14.6198 23.444 14.3296 23.4427C12.6185 23.4294 10.9079 23.4294 9.19779 23.4427C8.93155 23.4427 8.86099 23.3735 8.86232 23.1086C8.8783 19.7619 8.88628 16.4144 8.88628 13.066C8.88628 11.5688 8.87874 10.0708 8.86365 8.57182C8.86365 8.3575 8.90758 8.27896 9.14054 8.28029C10.9048 8.29094 12.6687 8.29094 14.4321 8.28029C14.6464 8.28029 14.6983 8.34818 14.6983 8.54653C14.6903 9.00047 14.6983 9.45441 14.6983 9.98423Z">
                            </path>
                            <path d="M6.55316 15.8443C6.55316 18.2564 6.55316 20.6699 6.55316 23.082C6.55316 23.3629 6.48127 23.4388 6.19906 23.4374C4.47737 23.4241 2.75568 23.4241 1.03399 23.4374C0.767751 23.4374 0.69986 23.3629 0.701191 23.1006C0.709178 18.2648 0.709178 13.4281 0.701191 8.59053C0.701191 8.34026 0.765089 8.27237 1.01669 8.2737C2.74991 8.28435 4.48048 8.28435 6.20838 8.2737C6.47462 8.2737 6.5465 8.33627 6.54517 8.6065C6.54783 11.0186 6.55316 13.4308 6.55316 15.8443Z">
                            </path>
                            <path d="M3.65878 0.243898C5.36804 0.243898 6.58743 1.45529 6.58743 3.1406C6.58743 4.75801 5.32145 5.95742 3.60819 5.96807C3.22177 5.97614 2.83768 5.90639 2.47877 5.76299C2.11985 5.61959 1.79344 5.40546 1.51897 5.13334C1.24449 4.86123 1.02755 4.53668 0.881058 4.17902C0.734563 3.82136 0.661505 3.43788 0.666231 3.05141C0.67555 1.42601 1.9362 0.242566 3.65878 0.243898Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on LinkedIn</span>
                    </a>
                

                
                    <a href="https://github.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="28"
                             height="27"
                             viewBox="0 0 28 28"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M16.7228 20.6334C17.5057 20.5527 18.2786 20.3944 19.0301 20.1608C21.3108 19.4193 22.5822 17.8259 22.963 15.4909C23.1228 14.5112 23.1814 13.5287 22.9883 12.5437C22.8106 11.6423 22.4013 10.8028 21.8007 10.1076C21.7526 10.0605 21.7197 10 21.7064 9.934C21.6931 9.86799 21.7 9.79952 21.7262 9.73748C22.0856 8.6206 21.9711 7.51969 21.601 6.42677C21.582 6.3497 21.5345 6.2827 21.468 6.23923C21.4016 6.19577 21.3211 6.17906 21.2429 6.19248C20.7329 6.21649 20.2313 6.33051 19.7611 6.52928C19.1103 6.7908 18.4899 7.12198 17.9104 7.51703C17.84 7.56996 17.7581 7.60551 17.6713 7.62078C17.5846 7.63605 17.4954 7.6306 17.4112 7.60489C15.2596 7.05882 13.0054 7.06203 10.8554 7.61421C10.7806 7.63586 10.7018 7.63967 10.6253 7.62534C10.5487 7.611 10.4766 7.57892 10.4148 7.53167C9.64788 7.03247 8.85171 6.58918 7.96368 6.33359C7.65781 6.24338 7.34123 6.19458 7.02239 6.18849C6.94879 6.17986 6.87462 6.19893 6.81432 6.242C6.75402 6.28507 6.71191 6.34904 6.69621 6.42145C6.32342 7.51437 6.2209 8.61527 6.56307 9.73348C6.59635 9.84264 6.64694 9.93316 6.54177 10.0516C5.47666 11.2604 5.09988 12.6834 5.19574 14.2676C5.2663 15.4244 5.46201 16.5466 6.01454 17.5769C6.84399 19.1171 8.21664 19.9119 9.85158 20.3352C10.3938 20.4706 10.9444 20.5698 11.4998 20.632C11.5384 20.7492 11.4506 20.7798 11.408 20.8291C11.1734 21.1179 10.9894 21.4441 10.8634 21.7942C10.7622 22.0458 10.8315 22.4039 10.6065 22.5516C10.263 22.7766 9.83827 22.8485 9.42421 22.8871C8.17936 23.0056 7.26471 22.4877 6.6283 21.4348C6.25552 20.8184 5.76956 20.3325 5.08523 20.0663C4.76981 19.9325 4.42139 19.8967 4.08537 19.9638C3.7898 20.029 3.73788 20.1901 3.93891 20.4111C4.03639 20.5234 4.14989 20.6207 4.27575 20.6999C4.9796 21.1318 5.51717 21.7884 5.80152 22.5636C6.37002 23.9973 7.48039 24.5697 8.93825 24.6323C9.43741 24.6575 9.93768 24.615 10.4254 24.5058C10.5892 24.4672 10.6531 24.4872 10.6517 24.6762C10.6451 25.4936 10.6637 26.3123 10.6517 27.131C10.6517 27.6635 10.1684 27.9297 9.58663 27.7393C8.17396 27.2671 6.84977 26.5631 5.66838 25.656C2.59555 23.2891 0.720966 20.1861 0.217704 16.3376C-0.357453 11.9127 0.911353 8.00824 3.98551 4.73881C6.11909 2.42656 8.99932 0.939975 12.1203 0.540191C16.5351 -0.0601815 20.4347 1.14323 23.7232 4.16373C26.2449 6.47869 27.724 9.37672 28.1048 12.7726C28.5828 17.0325 27.3686 20.7945 24.4768 23.9827C22.9762 25.6323 21.0956 26.8908 18.9982 27.6488C18.8783 27.6927 18.7585 27.738 18.636 27.7726C18.0356 27.9404 17.6189 27.6395 17.6189 27.0098C17.6189 25.7452 17.6308 24.4806 17.6295 23.2159C17.6329 22.9506 17.6128 22.6856 17.5696 22.4238C17.4325 21.6664 17.3419 21.484 16.7228 20.6334Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on GitHub</span>
                    </a>
                

                
                    <a href="https://ncbiinsights.ncbi.nlm.nih.gov/"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="26"
                             height="26"
                             viewBox="0 0 27 27"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M23.7778 26.4574C23.1354 26.3913 22.0856 26.8024 21.636 26.3087C21.212 25.8444 21.4359 24.8111 21.324 24.0347C19.9933 14.8323 14.8727 8.80132 6.09057 5.85008C4.37689 5.28406 2.58381 4.99533 0.779072 4.99481C0.202773 4.99481 -0.0229751 4.83146 0.00455514 4.21479C0.0660406 3.08627 0.0660406 1.95525 0.00455514 0.826734C-0.0413285 0.0815827 0.259669 -0.0193618 0.896534 0.00266238C6.96236 0.222904 12.3693 2.24179 16.9889 6.16209C22.9794 11.2478 26.1271 17.7688 26.4372 25.648C26.4629 26.294 26.3179 26.5271 25.6609 26.4684C25.0827 26.417 24.4991 26.4574 23.7778 26.4574Z">
                            </path>
                            <path d="M14.8265 26.441C14.0924 26.441 13.2371 26.6795 12.6626 26.3786C12.0092 26.0372 12.3781 25.0644 12.246 24.378C11.1154 18.5324 6.6849 14.5497 0.74755 14.1001C0.217135 14.0615 -0.0104482 13.9422 0.0134113 13.3659C0.0519536 12.1454 0.0482829 10.9213 0.0134113 9.69524C-0.00127145 9.14464 0.196946 9.03268 0.703502 9.04736C9.21217 9.27128 16.5994 16.2511 17.2804 24.7231C17.418 26.4446 17.418 26.4446 15.6579 26.4446H14.832L14.8265 26.441Z">
                            </path>
                            <path d="M3.58928 26.4555C2.64447 26.4618 1.73584 26.0925 1.06329 25.4289C0.39073 24.7653 0.00933763 23.8617 0.0030097 22.9169C-0.00331824 21.9721 0.365937 21.0635 1.02954 20.3909C1.69315 19.7184 2.59675 19.337 3.54156 19.3306C4.48637 19.3243 5.39499 19.6936 6.06755 20.3572C6.7401 21.0208 7.1215 21.9244 7.12782 22.8692C7.13415 23.814 6.7649 24.7226 6.10129 25.3952C5.43768 26.0677 4.53409 26.4491 3.58928 26.4555Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI RSS feed</span>
                    </a>
                
            </div>
        </div>
    

    <div data-testid="gridContainer"
         class="grid-container ncbi-footer__container">
        <div class="grid-row ncbi-footer__main-content-container"
             data-testid="grid">
            
                <div class="ncbi-footer__column">
                    
                        <p class="ncbi-footer__circled-icons-heading">
                            Connect with NLM
                        </p>
                    

                    <div class="ncbi-footer__circled-icons-list">
                        
                            <a href=https://twitter.com/nlm_nih class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="32"
                                     height="32"
                                     viewBox="0 0 40 40"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on X (formerly known as Twitter)</span>
                            </a>
                        

                        
                            <a href=https://www.facebook.com/nationallibraryofmedicine class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="13"
                                     height="24"
                                     viewBox="0 0 13 24"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M4.11371 23.1369C4.11371 23.082 4.11371 23.0294 4.11371 22.9745V12.9411H0.817305C0.6709 12.9411 0.670898 12.9411 0.670898 12.8016C0.670898 11.564 0.670898 10.3287 0.670898 9.09341C0.670898 8.97903 0.705213 8.95158 0.815017 8.95158C1.8673 8.95158 2.91959 8.95158 3.97417 8.95158H4.12057V8.83263C4.12057 7.8055 4.12057 6.7738 4.12057 5.74897C4.1264 4.92595 4.31387 4.11437 4.66959 3.37217C5.12916 2.38246 5.94651 1.60353 6.95717 1.1921C7.64827 0.905008 8.3913 0.764035 9.13953 0.778051C10.0019 0.791777 10.8644 0.830666 11.7268 0.860404C11.8869 0.860404 12.047 0.894717 12.2072 0.90158C12.2964 0.90158 12.3261 0.940469 12.3261 1.02968C12.3261 1.5421 12.3261 2.05452 12.3261 2.56465C12.3261 3.16857 12.3261 3.7725 12.3261 4.37642C12.3261 4.48165 12.2964 4.51367 12.1912 4.51138C11.5369 4.51138 10.8804 4.51138 10.2261 4.51138C9.92772 4.51814 9.63058 4.5526 9.33855 4.61433C9.08125 4.6617 8.84537 4.78881 8.66431 4.97766C8.48326 5.16652 8.3662 5.40755 8.32972 5.66661C8.28476 5.89271 8.26027 6.1224 8.25652 6.35289C8.25652 7.19014 8.25652 8.02969 8.25652 8.86923C8.25652 8.89439 8.25652 8.91955 8.25652 8.95615H12.0219C12.1797 8.95615 12.182 8.95616 12.1614 9.10714C12.0768 9.76596 11.9876 10.4248 11.9029 11.0813C11.8312 11.6319 11.7626 12.1824 11.697 12.733C11.6719 12.9434 11.6787 12.9434 11.4683 12.9434H8.26338V22.899C8.26338 22.979 8.26338 23.0591 8.26338 23.1392L4.11371 23.1369Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on Facebook</span>
                            </a>
                        

                        
                            <a href=https://www.youtube.com/user/NLMNIH class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="21"
                                     height="15"
                                     viewBox="0 0 21 15"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M19.2561 1.47914C18.9016 1.15888 18.5699 0.957569 17.2271 0.834039C15.5503 0.678484 13.2787 0.655608 11.563 0.65332H9.43556C7.71987 0.65332 5.4483 0.678484 3.77151 0.834039C2.43098 0.957569 2.097 1.15888 1.74242 1.47914C0.813665 2.32097 0.619221 4.62685 0.598633 6.89384C0.598633 7.31781 0.598633 7.74101 0.598633 8.16345C0.626084 10.4121 0.827391 12.686 1.74242 13.521C2.097 13.8412 2.4287 14.0425 3.77151 14.1661C5.4483 14.3216 7.71987 14.3445 9.43556 14.3468H11.563C13.2787 14.3468 15.5503 14.3216 17.2271 14.1661C18.5676 14.0425 18.9016 13.8412 19.2561 13.521C20.1712 12.6929 20.3725 10.451 20.3999 8.22064C20.3999 7.74025 20.3999 7.25986 20.3999 6.77946C20.3725 4.54907 20.1689 2.30724 19.2561 1.47914ZM8.55942 10.5311V4.65201L13.5601 7.50005L8.55942 10.5311Z"
                                          fill="white" />
                                </svg>
                                <span class="usa-sr-only">NLM on YouTube</span>
                            </a>
                        
                    </div>
                </div>
            

            
                <address class="ncbi-footer__address ncbi-footer__column">
                    
        <p>
            <a class="usa-link usa-link--external"
            href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/%4038.9959508,
            -77.101021,17z/data%3D!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb%3A0x19156f88b27635b8!8m2!3d38.9959508!
            4d-77.0988323"
            rel="noopener noreferrer" target="_blank">National Library of Medicine
            <br/> 8600 Rockville Pike<br/> Bethesda, MD 20894</a>
        </p>
    
                </address>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://www.nlm.nih.gov/web_policies.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    Web Policies

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    FOIA

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
    

    HHS Vulnerability Disclosure

    
</a>

                        </li>
                    
                </ul>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://support.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    Help

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://www.nlm.nih.gov/accessibility.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    Accessibility

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://www.nlm.nih.gov/careers/careers.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    Careers

    
</a>

                        </li>
                    
                </ul>
            
        </div>

        
            <div class="grid-row grid-col-12" data-testid="grid">
                <ul class="ncbi-footer__bottom-links-list">
                    
                        <li class="ncbi-footer__bottom-list-item">
                            








<a href="https://www.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    NLM

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            








<a href="https://www.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    NIH

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            








<a href="https://www.hhs.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
    

    HHS

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            








<a href="https://www.usa.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
    

    USA.gov

    
</a>

                        </li>
                    
                </ul>
            </div>
        
    </div>
</footer>

    


        
        
    
  <script  type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/pinger/pinger.js"> </script>


    
        

<button class="back-to-top" data-ga-category="pagination" data-ga-action="back_to_top">
    <label>Back to Top</label>
    <svg class="usa-icon order-0" aria-hidden="true" focusable="false" role="img">
        <use xlink:href="/static/img/sprite.svg#arrow_upward"></use>
    </svg>
</button>
    


        
    
    
    
        
    <script type="application/javascript">
    window.ncbi = window.ncbi || {};
    window.ncbi.pmc = window.ncbi.pmc || {};
    window.ncbi.pmc.options = {
        logLevel: 'INFO',
        
        staticEndpoint: '/static/',
        
        citeCookieName: 'pmc-cf',
    };
</script>
    <script type="module" crossorigin="" src="/static/assets/base-370d5dd6.js"></script>
    
    <script type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/jquery/jquery-3.6.0.min.js">&#xA0;</script>
    <script type="text/javascript">
        jQuery.getScript("https://cdn.ncbi.nlm.nih.gov/core/alerts/alerts.js", function () {
            galert(['div.nav_and_browser', 'div.header', '#universal_header', '.usa-banner', 'body > *:nth-child(1)'])
        });
    </script>


    <script type="text/javascript">var exports = {};</script>
     <script src="/static/CACHE/js/output.13b077bc3ffd.js"></script>

    <script type="module" crossorigin="" src="/static/assets/article-917ba005.js"></script>
    
    

    </body>
</html>
